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2 Abstract 
Paper I  
To investigate the hemodynamic response of calcium-sensitization and PDE3-inhibitions 
during hypothermia and rewarming we administered levosimendan in an experimental model 
of accidental hypothermia. 
Paper II  
In an identical experimental model of hypothermia we aimed to investigate the hemodynamic 
effects of systemic vascular resistance reduction during hypothermia and rewarming. This 
was achieved by administration of nitroprusside. 
Paper III  
To further investigate the hemodynamic effects of levosimendan and nitroprusside in the 
rewarming scenario, a modified version of the experimental model from paper I and II was 
applied. Organ perfusion was measured during and after rewarming.   
Main results and conclusions  
Hypothermia and rewarming depressed hemodynamic function in all control groups. 
Levosimendan improved cardiac output more than nitroprusside, while nitroprusside reduced 
vascular resistance. Nitroprusside demonstrated to superiorly improve organ blood flow. 
The hemodynamic state after rewarming seems to be a combination of reduced cardiac 
function and unwanted systemic vasoconstriction. Organ perfusion is not limited only by 
available CO, but also possibly altered autoregulation and vascular pathology.   
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3 Abbreviations - sorted by occurrence 
 
HCD: Hypothermia-induced cardiac 
dysfunction 
CO: Cardiac output 
SV: Stroke volume 
FFA: Free fatty acid 
cTnI: Cardiac troponin I  
PKA: Protein kinase A 
BV: Blood volume  
SVR: Systemic vascular resistance 
MAP: Mean arterial pressure 
RAAS: Renin-angiotensin-aldosterone 
system 
LV: Left ventricle 
CPB: Cardiopulmonary bypass  
PV: Plasma volume  
PCOP: Plasma colloid pressure 
ICOP: Interstitial colloid pressure 
CBF: Cerebral blood flow 
OBF: Organ blood flow 
MBF: Myocardial blood flow 
RBF: Renal blood flow 
SBF: Splanchnic blood flow 
CPR: Cardio pulmonary resuscitation 
ECMO: Extra corporal membrane 
oxygenation 
COMT: catechol-O-metyl transferase 
Emax:  Maximum response 
EC50: Half maximal effective 
concentration  
HR: Heart rate 
CI: Cardiac index 
PDE3: Phosphodiesterase III 
cAMP: cyclic AMP 
LS: Levosimendan 
SNP: Sodium nitroprusside 
PRSW: Preload recruitable stroke work 
ESP: End-systolic pressure 
dP/dtmax: Maximum rate of LV pressure 
change  
dP/dtmin: Minimum rate of LV pressure 
change  
Tau: The isovolumic relaxation constant 
SW: Stroke work 
DO2: Oxygen delivery  
DO2: Oxygen consumption 
ESPVR: End systolic-pressure volume 
relationship 
PDM: Disintegration per minute 




CaO2: Arterial blood oxygen content 
CvO2: Venous blood oxygen content 
CMRO2: Cerebral metabolic rate of 
oxygen  
MVO2: Cardiac oxygen consumption  
GFR: Glomeruli filtration rate
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5 Introduction 
5.1 Grading of hypothermia 
The dangers of hypothermia correlate to temperature depth and duration1. To aid health 
professionals and scientists, grading systems have been developed to simplify clinical 
decision making and treatment procedures. As in many areas of medicine, there has been a 
gradual development, and the grading of hypothermia have been changed to coincide with 
available knowledge. In 1974 Popovic defined hypothermia as a core temperature <35°C, and 
the international community still agrees on this definition2. Further, Popovic sub-classified 
hypothermia as mild (35-32°C), moderate (32-22°C), deep (22-8°C) or profound (<8°C). In 
1994 Danzl classified hypothermia as mild (35-32°C), moderate (32- 28°C), severe (28-
20°C), or profound (<20°C)1. The European Resuscitation Council’s guidelines for treating 
hypothermic patients use a modified version of this system, without a profound group3. A 
more simplified scaling was proposed by Polderman in 20094. Mild hypothermia (35-34°C), 
moderate (34-30°C), and severe (<30°C). This grading is used by the American Heart 
Association and in University Hospital of Northern-Norway 2014 guidelines for treating 
accidental hypothermia5.  
 
5.2 Epidemiology of hypothermia 
The yearly incidence and mortality of isolated hypothermia is low6. However, it is associated 
with a high lethality and is a common complication in surgery and trauma situations. 
Epidemiological studies performed in 1970s show 30-80% lethality among hypothermic 
patients.  In more recent studies, lethality has fallen to around 30%7-10. It is important to stress 
that the hypothermic patient population is heterogenic, and total lethality rate hide the 
complexity surrounding chance of survival7,8,10. 
 
5.2.1 Hypothermic patients 
Most epidemiological studies on hypothermia are small, single-center and with few patients. 
In the urban situation, Roeggla et al, (80 patients, 1991-1998 in Vienna), Megarbane et al (81 
patients, 1981 – 1998 in Paris) and van der Ploeg et al (84 patients, 2000 – 2008 in 
Amsterdam) have described the hypothermic epidemiology. The results are consistent 
between the three studies7,8,10. Based on autopsy data from 63 hypothermia deaths in 
Alabama, USA, Taylor et al concluded that death due to hypothermia can be divided in two 
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main groups; “the old and comorbid” and “the young intoxicated”11. This is consistent with 
the findings of Roeggla, Megarbane and van der Ploeg were 50 – 85 % were male, the 
average age was 47 - 65 years, 22–35 % were found indoors and the total mortality was 28 – 
35 %.  
 
These studies show a discrepancy in demographics, comorbidity and mortality between the 
patients found indoor and those found outside. The average age of patients found indoor was 
67 – 69 years of age and 42 – 50 in the outdoor groups. Megarbane et al investigated the 
difference in comorbidity between the two groups and found that the patients found indoors 
had higher rate of chronic illness. Van der Ploeg et al made no such analysis, but their 
survival data show a higher median age in non-survivors (68 years) than the survivor group 
(38 years)7,8,10. 
 
Variable Found inside Found outside 
Age (years) 67 – 69 42 – 50 
Intoxicated (%) 19  76  
Septicemia (%) 30 6  
Neuropsychiatric (%) 27  12  
Hypo-glycemia/thyroidism (%) 13  6  
Cardiac arrhythmias (%) 5  - 
Unspecified pathology (%) - 6  
Survival (%) 44 - 81  6 - 11  
 
 
5.2.2 Trauma patients and hypothermia: 
Hypothermia is an independent mortality risk-factor in trauma patents12,13, and 9.7% of 
hypothermia patients was traumatically injured14. Unconsciousness, hemorrhage, hypoxia and 
hypoperfusion are all important factors predisposing trauma patients to hypothermia15. In the 
US National Trauma Data Bank, 1.9 % of patients where hypothermic and the mortality rate 
was 25 % versus 3 % compared to patients with a core temperature >35°C16. Wang et al. 
showed a linear relationship between degree of hypothermia and mortality in trauma patients, 
with 100 % mortality at core temperature <32°C independent of injury severity score14. In 
Melbourne, Australia, Ireland et al. found that 13.25% of 737 trauma patients were 
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hypothermic upon hospital admission12. A mortality of 29.9 % was found in these patients 
versus 5.98 % in non-hypothermic patients. In addition, hypothermic trauma patients stay 
longer in hospital and have a lower chance of being discharged to their home12.  
  
5.3 The cardiovascular pathophysiology of hypothermia and rewarming shock  
From the clinical perspective, the cardiovascular-, respiratory- and cerebral depression during 
hypothermia are critical: All hypothermic patients stand in risk of cardiac arrest, apnea or loss 
of consciousness1,17,18. Depending on the degree and prolongation of the hypothermic period 
the pathological changes of cooling manifest as acute and prolonged organ damage or failure1. 
One clinical consequence of hypothermia-induced hemodynamic pathology is cardiovascular 
dysfunction; rewarming shock, at low core temperatures and during rewarming. Investigators 
have demonstrated that hypothermia and rewarming is associated with changes in circulating 
blood volume, cardiac contractility and vascular resistance19-23. 
 
5.3.1 Hypothermia-induced cardiac dysfunction (HCD) 
HCD is evident both from clinical and preclinical data20,21. Clinically, this is manifest as a 
lowered blood pressure and evidence of depressed organ perfusion1,21. In experimental 
models, investigators have demonstrated lowered cardiac output (CO), stroke volume (SV) 
and cardiac contractile force during and after rewarming20,24,25. Further, investigators have 
attempted to describe and explain the physiological and cellular changes caused by 
hypothermia that depress the contractile properties of the heart. Findings show that 
cardiomyocyte ATP-availability, electrochemical homeostasis, endocrine control and cross-
bridge formation all seems to be altered during hypothermia, and possibly contribute to the 
development of HCD. The following subsection aim to present a detailed description of these 
changes and their possible contribution to HCD. 
 
5.3.1.1 Cardiac metabolism and ATP production  
A balance between production and usage of ATP is an absolute necessity to cellular function 
and depressed production is associated with cellular dysfunction and cell death26. The heart 
depends on a great production of ATP to drive the actin-myosin cross-bridge complex and 
maintain electrochemical homeostasis27. Bui-Mong-Hung et al. investigated the cardiac tissue 
content of high-energy phosphates during hypothermia in vitro and found normal levels after 
cooling to 13°C28. These findings were supported by Tveita et al. who also demonstrated that 
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high-energy phosphate levels are preserved during hypothermia at 25°C, and after rewarming 
in an in vivo dog model24. Contrary to these findings, Tveita later showed reduced ATP after 
four hours of hypothermia at 15°C and after rewarming, in an in vivo rat model showing 
significant reduction in cardiac functional variables29.  
 
Production of high-energy phosphates depend on oxygen availability, metabolic substrate and 
mitochondrial integrity30. Cardiomyocyte damage and stress cause a shift in metabolic 
substrate from free fatty acids (FFA) to glucose and FFA oxidation has been seen as an 
indicator for cardiomyocyte health and effective metabolism31. In an attempt to investigate the 
effect of hypothermia and rewarming on myocardial substrate selection, Steigen et al. 
described a shift towards FFA oxidation, with reduction in both substrates, at 15°C. After 
rewarming, only FFA returned to normal levels32. Steigen et al. theorized that the shift 
towards FFA might explain the myocardial oxygen wastage described after rewarming 24,33. In 
a second study on rat hearts they demonstrated lower cardiac performance and elevated post-
hypothermic intracellular Ca2+ in isolated hearts that were provided exogenous FFA in 
addition to glucose34. Aasum et al, demonstrated improved cardiac performance if 
carbohydrate metabolism was pharmacologically induced during rewarming35. However, in 
dogs cooled to 25°C and rewarmed, Steigen et al. found conflicting results to that of the rat. 
Like in the rats, FFA and glucose uptake and usage is decreased during hypothermia, however 
rewarming normalized glucose oxidation while FFA oxidation was reduced25. Tveita et al also 
found similar results in a second study on dogs cooled to 25°C24. 
 
5.3.1.2 Intracellular ion balance and pH 
8-10 % of cardiac metabolism is utilized to uphold intracellular ion balance27. In hypothermia, 
Na+/K+-ATPase activity is reduced36. In isolated  cardiomyocytes, hypothermia have 
demonstrated to elevate intracellular Na+37,38, and potentiate hypoxia-induced Na+ 
accumulation39. In vivo, Tveita et al. found elevated cardiomyocyte cytosolic volume after 4 
hours at 15°C in rats. This was further elevated upon rewarming, also including intracellular 
and mitochondrial volume. The investigators interpreted this as evidence of Na+ accumulation 
during hypothermia and rewarming40.  
 
As with Na+, cooling causes a disruption of cellular Ca2+ homeostasis41. In isolated 
cardiomyocytes Liu et al showed Ca2+ accumulation due to reversal of the Na+/Ca2+ 
exchanger42. In isolated hearts, Aasum et al made the same discoveries during hypothermia, 
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and also showed elevated Ca2+ after rewarming35. These findings where later confirmed by 
Kondratiev and Wold using an in vivo model43,44. Cardiac Ca2+ homeostasis is in 
synchronization with the bi-phasic nature of the cardiac cycle and hypothermia-induced 
bradycardia affect this balance45. Hypothermia prolong action potential duration and the 
opening of, and flux through, the L/T-type Ca2+ channels, which has been proposed as an 
important mechanism of Ca2+ accumulation, in addition to reversal of the Na+/Ca2+ exchanger 
46. However, Bjørnstad et. al proposed that Ca2+-accumulation caused the prolongation of 
action potential duration, not the other way around47. In addition to altered sarcolemmal Ca2+-
fluxes, hypothermia seems to disrupt intracellular Ca2+ handling by the sarcoplasmatic 
reticulum and the mitochondria42,48. The elevated cellular Ca2+ has been proposed to be 
buffered by the mitochondria, and that this cause mitochondrial Ca2+-overload49. Ca2+ is an 
important regulator of mitochondrial function and Ca2+ is known to trigger cellular 
apoptosis50,51. 
 
In ischemia, the anaerobic metabolic production of lactate and accumulation of H+ is thought 
be a key mechanism underlying cellular acidosis52. This may cause cellular swelling as the 
H+/Na+-exchanger contribute to further influx of Na+ when H+ is expelled in exchange for 
Na+. Elevated levels of H+ may cause depressed ATP production, reduced contractility and 
Ca2+ buffering53. In hypothermia, Ellis et al. demonstrated that cooling to 20°C did not alter 
cellular pH54 and Kusuoka et al. later reproduced these findings at 30°C55. Using magnetic 
resonance imaging in vivo, Swain et al. documented elevated pH (7.0 to 7.2) in intact sheep 
hearts cooled to 26°C56. Boutillier argued that the H+/Na+-exchanger is affected by 
hypothermia52. This has been confirmed by Hoshino, who demonstrated that the H+/Na+-
exchanger activity is reduced by 50% when subjected to a given H+ load at 25°C, this 
reduction in H+/Na+-exchanger activity would stand in contrast to the findings of Ellis and 
Kusuoka, as accumulated H+ would lead to reduced pH. 
However, Hoshino also demonstrated that cellular buffering capacity was significantly 
elevated at 25°C57. This might explain why pH remain unchanged during hypothermia.  
 
5.3.1.3 Sympathetic control:  
The hormonal response to cooling and hypothermia have been investigated in multiple 
species, with conflicting findings. In rats, cooling to 22°C elevated aldosterone, angiotensin 
II, epinephrine, norepinephrine and dopamine58,59. In humans, perioperative hypothermia at 
35°C has shown to increase blood levels of epinephrine and norepinephrine, which do not 
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normalize after rewarming60. In unanaesthetized men, Hiramatsu made the same 
discoveries61. Kuroda et al. demonstrated that RAAS hormones also are increased in humans 
after cooling to 30°C. Unlike epinephrine and norepinephrine, all hormones, expect 
aldosterone, is normalized after rewarming62. On the other hand, Turley et al. found no 
alteration in catecholamine levels in 2-week-old lambs after cooling to 14°C63. This resonates 
with Chernow, who argued that hypothermia causes a sympathetic nervous system “switch-
off”. They showed that, while cooling from 37°C to 30°C elevated epinephrine and 
norepinephrine, continued cooling below 29°C reduced catecholamine levels to 
prehypothermic values64. They attributed the hypotensive state observed in hypothermic 
patients to this “switch-off”. In an recent study from our lab, we show that the reduced 
influence of the autonomic system continues throughout rewarming65.  
 
5.3.1.4 Altered myofilament Ca2+sensitivity  
Regulation of myofilament cross-bridge formation and contractile force is multifaceted. Ca2+ 
fluxes, post-translational regulation by myofilament phosphorylation, pH and ATP 
availability all regulate the speed and effectiveness of the cross-bridge cycle53. 
Phosphorylation of myofilaments such as troponin I, troponin T, myosin binding protein C 
and myosin light chain kinase is tightly regulated to match the physiological demand of 
cardiac contractility and relaxation66. Phosphorylation regulate cross-bridge rate, Mg-ATPase, 
myofilament sliding velocity and most notably myofilament Ca2+sensitivity67,68. Han et al 
investigated the effects on hypothermia on myofilament Ca2+sensitivity in isolated papillary 
muscle and found significant reduction during hypothermia. This resonates with findings 
from other investigators42,53. Han further showed that the hypothermia-induced reduction in 
Ca2+-sensitivity continues after rewarming, and is associated with increased phosphorylation 
of the cardiac troponin I main site, Ser23/2420. In a second study, Schaible et al. showed 
progressive increase in Ser23/24 phosphorylation and active protein kinase A (PKA), its main 
activator, during hypothermia. Upon rewarming, both was reduced, however not to pre-
hypothermic levels69. In a recent study, Scahible et al. also proposed the importance of 
reactive oxygen species as a contributing factor to the reduced Ca2+-sensitivity70. 
 
5.3.2 Vascular function and rheology in rewarming shock  
Arterial perfusion pressure and CO depends on cardiac contractility, blood volume (BV), 
vascular resistance (SVR), and vascular compliance71. Like cardiac contractility, BV, SVR 
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and compliance are all altered by hypothermia and rewarming19,22,72. The following section 
aim to present a brief introduction to these changes and focus on how vascular physiology is 
affected by hypothermia and rewarming, and possibly contribute to rewarming shock. 
 
5.3.2.1 Systemic vascular resistance 
In fluid dynamics, resistance to flow is calculated with an adaptation of Ohm’s law, and can 
be calculated from pressure decline and flow (SVR =
MAP−CVP
𝐶𝑂
)73. Regulation of SVR depends 




) attempts to portrait the determining factors underlying vascular 
resistance and it is readily used in physiological and medical education to illustrate the 
regulatory mechanisms of flow of blood in the vasculature74,75. However, while an useful 
illustration, it assumes multiple unphysiological conditions to be true, most notably that blood 
is a Newtonian liquid and that large artery flow is laminar, both not true74.  
 
The relationship between SVR, CO, MAP and central venous pressure show that changes in 
one variable affect the others. If no compensation, therapeutic or physiological, occurs, a 
lowered SVR, normal MAP and SVP necessitate improved CO. Further, as the heart pump 
against the aortic blood pressure, elevated SVR and afterload, forces the heart to generate 
greater force to maintain CO73. Pathological elevation in SVR, such as a hypertensive crisis or 
administration of exogenous vasoconstrictors are known to depress CO76  
 
Elevation of SVR was described in early hemodynamic research of hypothermia, and has 
been documented in different species and experimental models in later works22,77. Bullard et 
al. concluded that SVR elevation during hypothermia is caused by increased blood 
viscosity22,78. As blood is a non-Newtonian liquid, the viscosity-sheer rate relationship is non-
linear, has sheer-thinning properties, and viscosity increases as flow and pressure is reduced, 
as during hypothermia79,80. Hypothermia is associated with hematological changes associated 
with elevated viscosity, hemoconcentration, altered erythrocyte morphology and sludging of 
blood81-85. Although few investigations have been conducted, rewarming seems to normalize 
blood viscosity86. Despite this, multiple studies have demonstrated a continued increase in 
SVR during and after rewarming24,77,87. If this elevated SVR is a physiological mechanism to 
compensate for lowered CO or the result of vascular pathology or a result of autonomic 
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dysregulation is a topic in need of further investigation, as this, to my best understanding, is 
not well described. 
 
In classic physiology teaching, regulation of SVR is achieved by neurohormonal and 
endothelial manipulation of vessel radius by smooth muscle vasoconstriction or dilatation73. 
As highlighted in the previous section, hypothermia and rewarming is associated with 
changes in endogenous catecholamine and renin-angiotensin-aldosterone-system (RAAS) 
levels. While many studies indicate an elevation in RAAS levels, the data seems inconsistent 
and dependent on depth and prolongation of the hypothermic period, as well as the 
investigated species58,62,64. In addition to these changes, Fuhrman et al. demonstrated reduced 
enzymatic breakdown of epinephrine at low temperatures88.  
 
While the endogenous levels of vasoactive substances and the activity of autonomic nervous 
system during hypothermia is not fully understood, investigators have demonstrated changes 
in arterial and venous function and responsiveness to  and -receptor agonists, as well as 
other vasoactive substances at low temperatures. In veins, Webb-Peploe et al. found that 
cooling dogs caused venoconstriction89. Shepherd and Vanhoutte found increased sensitivity 
to multiple vasoactive substances and reduced threshold for contraction in saphenous, 
cutaneous, mesenteric and muscular vein from dog, after cooling90,91. This resonate with 
findings from other investigations and in other species92-95. In arteries, Bandick et al. found 
increased effects of norepinephrine in rabbit femoral artery96. In rat, Harker et al showed the 
same elevation in tail arteries, but not in the femoral artery or the aorta97. In addition, in rat, 
Dietrichs et al. found elevated MAP and reduced CO after epinephrine infusion98. Moreover, 
while the vascular sensitivity to vasoactive substances is increased, the contractile force of 
vascular smooth muscle is decreased with falling temperature 99. 
 
Lastly, the integrity of the endothelial layer of vascular smooth muscle cells are important in 
regulation of vessel vasoconstriction and dilatation. Hypothermia is associated with impaired 
endothelial-dependent vasodilatation in coronary arteries of dogs, while endothelial 
independent vasodilatation is maintained. After rewarming this impairment was 
normalized100. Later, Cooper et al. showed that hypothermic circulatory arrest affected 
endothelial-dependent vasodilatation in the large renal arteries and pulmonary veins, but not 
in the cerebral vasculature, in vivo. This was, however, found in vitro. Cooper attributed this 
to damage to, or dysfunction of vascular endothelial cells101 while smooth muscle function is 
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preserved. This is in agreement with a review by Hansen, who show that the literature 
strongly suggest hypothermia to cause major changes to endothelial structure and function102. 
 
5.3.2.2 Vascular compliance  
Vascular compliance is the innate ability of a vessel to distend and expand its volume with 
increased transmural pressure. Vessel compliance is an important determinant of blood 
pressure and organ perfusion71. The elastic properties of the large vessels provide a 
Windkessel-effect: Transforming the pulsatile flow of the aorta to a linear flow in the 
arterioles and capillaries. Further, this elastic system provides a shock absorbent, alleviating 
late systolic afterload103,104. There is a strong association between chronic increase in arterial 
stiffness, reduced vascular compliance and cardiovascular disease105,106. However, rapid 
changes in compliance and  stiffness of arteries do occur in response to autonomic regulation, 
physical stress and acute vascular pathology, and has negative effects on CO107-109. Multiple 
investigators have demonstrated that vascular compliance is reduced during 
hypothermia72,110,111. In a study by Deal et al. on vascular compliance in sheep lung during 
cooling on cardiopulmonary-bypass (CPB), a decreased compliance was found that 
normalized upon rewarming110.  
 
5.3.2.3 Circulating blood volume and composition:    
The importance of blood volume (BV) as a factor for stroke volume and organ perfusion in 
circulatory physiology is well established71,73. Hypothermia-induced changes in plasma and 
blood volume (PV) was described by Rodbard et al. already in 1951, reporting a reduction in 
PV and BV after cooling rabbits to 29°C23. Later, several investigators have demonstrated 
similar findings in different species and protocols of hypothermia19,112-114. It seems, to be a 
discrepancy between the investigators in their understanding of the mechanisms underlying 
PV and BV loss during hypothermia. Based on his 1951 study, Rodbard advocated that the 
loss of PV and BV resulted from vascular trapping of circulating BV. This was rationalized 
with findings of lowered erythrocyte volume, followed by a theoretical deduction of fluid 
displacement23. The findings were later supported by D`Amato115. Later, Chen and Chein 
disputed this theory as they found reduced PV, increased thoracic lymphatic duct flow, 
elevated plasma colloid osmotic pressure (PCOP) and hematocrit in dogs cooled to 25°C. 
They contributed the loss of volume to transcapillary leakage of fluid due to hypothermia-
induced elevations in blood pressure114. Finally, in an attempt to determine the strength of 
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these theories Nose et al. aimed to elucidate on the relationship between interstitial fluid space 
and the vascular system during cooling to 30°C. Nose et al found reduced PV and increased 
PCOP, but no change in hematocrit or BV. Based on this they concluded that the primary 
force of PV loss is hypothermia-induced redistribution of circulating blood to circulatory beds 
of high compliance116. Nose explained the findings of Chen and Chein by referring to Green 
and Jackman who concluded that plasma loss could be explained by redistribution of blood to 
organs with high transvascular filtration coefficient for water and low reflection coefficient 
for protein, such as the splanchnic vascular bed111,112.  
 
After rewarming from 2 hours at 25°C in dogs, Fedor and Fisher found a normalization of PV 
and BV113. When Tveita et al. extended the hypothermic period to 4 hours at 15°C, more 
pronounced changes of plasma protein leakage were indicated. This persisted after rewarming 
accompanied by increased interstitial colloid osmotic pressure (ICOP), as well as reduced 
PV19. They concluded that extended hypothermia is associated with significant plasma fluid 
and protein loss, which is not mitigated by rewarming. These results resonate with Nose`s 
theory of fluid and protein leakage due to redistribution116.  
 
5.3.3 Organ perfusion in hypothermia and rewarming  
The previous section has described the consequence of hypothermia and rewarming on 
cardiac and vascular function. These changes are important in regulation of organ perfusion, 
and oxygenation. The following section will explore how such changes affect organ perfusion 
and in turn oxygen delivery. It will also look at how oxygen consumption is affected during 
hypothermia.  
 
5.3.3.1 Organ perfusion, hypothermia and rewarming   
Under normothermic conditions, vital organ blood flow is tightly regulated to maintain 
constant flow over a wide physiological range73. Lassen demonstrated this effectiveness in a 
classic study investigating cerebral blood flow (CBF) while changing MAP in intervals 
between 50 – 150 mmHg117. Further, in healthy humans, a 30% reduction in CO result in a 
10% reduction in CBF118. This has been attributed to organ specific autoregulation to secure 
local blood flow, and has been identified to all organs73,117,118. 
In states of hemodynamic shock, reduced organ perfusion is associated with elevated 
mortality119. Hypothermia is associated with depressed vital organ blood flow (OBF). In dogs, 
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cooling to 21ºC reduces CBF, myocardial (MBF), renal (RBF) and splanchnic blood flow 
(SBF) with 75, 60, 72 and 84 %, respectively81. 4 hours of hypothermia at 15ºC in rats, 
reduced CBF, MBF, RBF and SBF by 82, 91, 98 and 91% respectively19. In these two 
experiments, CO is reduced by 80 and 91%, respectively. After rewarming, total OBF was 
reduced by 3 % in the dogs, two hours after rewarming, while the total OBF the rats 
significantly reduced by an average of 67 % after rewarming. Moreover, CO was reduced by 
67 % in rats and only 14% in the dogs19,81.  
The discrepancy in OBF between these studies might be explained by the difference in 
experimental protocol. The rats suffered 4 hours at 15ºC – 13ºC against 30 minutes at 21ºC in 
the dog model. While CO was depressed in both protocols after rewarming, OBF was only 
depressed in the rats. The increased discrepancy between post-hypothermic CO and OBF in 
the rats might indicate failure of organ autoregulation of blood flow in combination with 
HCD.  
 
5.4 Treatment of hypothermia and rewarming shock 
Treatment of victims of accidental hypothermia has improved significantly in quality as 
medical knowledge and life-supporting procedures have progressed. This is evident as 
mortality of hypothermic patients has fallen from 80 %, in earlier reports, to ≈ 30 % in 
modern studies7,10,120-122. Treatment of severely hypothermic patients is multidisciplinary and 
rely on appropriate rewarming techniques, including respiratory and hemodynamic support, 
both invasive and non-invasive.  
 
5.4.1 Clinical guidelines of treatment of hypothermic patients: 
Multiple clinical guidelines to treat hypothermic patients exist1,3,5,18,123-125. First and foremost, 
hypothermic patients should be transported to a medical center capable of providing intensive 
care treatment and expertise in applying comprehensive rewarming techniques. Further, 
patients with low core temperature and hemodynamic instability, the availability of invasive 
rewarming and advanced hemodynamic support is needed. The regional guidelines at The 
University Hospital of Northern-Norway dictates that patients with a core temperature <28°C 
and/or an unstable hemodynamic situation should be transported directly to, the University 
Hospital of Northern-Norway, and not attempted to be rewarmed at smaller local hospitals5. 
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This mirrors the recommendations from Brown et al. 2012 New England Journal of Medicine 
review on treatment of accidental hypothermia18 
 
In the ICAR MEDCOM guidelines for avalanche rescue, patients with a core temperature 
<32°C and spontaneous circulation and respiration should be treated at a hospital with active 
heating. Victims with cardiac standstill treated with prehospital cardio-pulmonary 
resuscitation (CPR) and transported to a hospital providing extra corporal membrane 
oxygenation (ECMO) rewarming technique125.  
 
The safety and effectiveness of vasoactive substances in hypothermic patients have been 
questioned1,3,18. This skepticism might be well be reasoned, as little clinical evidence exists on 
the effects of hypothermia on pharmacodynamics- and pharmacokinetic changes. The 
international guidelines reflect this: The European Guidelines on cardiac resuscitation 
withstand the use of all pharmacological treatment <30°C3. This is mirrored in the new 
Norwegian national guidelines for treatment of accidental hypothermia, and highlighted by 
Brown et al18. The following section aim to focus at the experimental and clinical data 
available on the effect of hypothermia and rewarming on the pharmacodynamic and 
pharmacokinetic properties of common vasoactive substances.  
  
5.4.2 Pharmacological support: 
5.4.2.1 Pharmacokinetics of vasoactive drugs in hypothermia: 
Hypothermia is associated with changes in enzymatic activity, renal filtration rate, 
hemodynamics and fluid balance. Such alterations affect the pharmacokinetic properties of 
many vasoactive substances. In a review from 2010, van den Broek et. al. summarized 
findings from 39 studies investigating changes in the pharmacological properties of different 
therapeutic substances during hypothermia126. This data show that hypothermia is associated 
with decreased clearance and volume of distribution of important drugs used in the intensive 
care setting. Fentanyl, pentobarbital, atropine, ethanol, benzodiazepines, morphine, propofol 
and muscle relaxants all had decreased clearance, while verapamil and propranolol had 
increased clearance below 30°C127-139. Distribution volume was also significantly altered by 
hypothermia, and pharmacologic agents like theophylline, curare and morphine had 
decreased136-138,140, midazolam increased141, and barbiturates were subjected to both increased 
and decreased volume of distribution during hypothermia142,143.  
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Lastly, van den Broek et al. demonstrated altered pharmacodynamics of vasoactive substances 
important in acute and intensive care of hemodynamically unstable patients126. In their 
review, they present changed pharmacodynamic properties of epinephrine, isopenaline and 
dobutamine during hypothermia144,145. Following is a more detailed description on the 
documented changes, as well as other available studies.   
 
5.4.2.2  and -adrenergic agonists 
Hypothermia is associated with temperature- dependent changes in adrenergic receptors. 
Williams and Broadley demonstrated 1-supersensitivity after cooling to 30°C and 25°C146. 
This is supported by Dietrichs et al. who made similar findings in cardiomyocytes after 
cooling to 15°C in vitro, and in vivo showed that epinephrine elevated cardiac cAMP four-
fold at 15°C compared to 37°C98,145. On isolated rabbit hearts Riishede and Nielsen-Kudsk 
also demonstrated a supersensitivity of epinephrine at all temperatures during cooling to 
22°C144. Like the -receptor, vascular  receptor sensitivity is also significantly elevated after 
cooling. Flavahan and Vanhoutte, and Gomez et al. independently demonstrated this in both 
human and canine arteries and veins147,148.  
 
In addition to receptor specific changes, hypothermia seems to alter the pharmacokinetic 
properties of monoamines that are dependent on their removal from the synaptic cleft by 
catechol-O-metyl transferase (COMT)149. Cooling reduces enzymatic activity of COMT and 
increase the concentration of epinephrine and norepinephrine in the adrenergic-receptor 
vicinity88,149.    
 
5.4.2.2.1 Epinephrine 
Administration of exogenous epinephrine, and thus stimulation of cardiac and vascular 2, 1 
and 2 receptors, causes increased cardiac contractility, elevated cardiac output and peripheral 
vasodilatation during normothermia. In hypothermic cardiac tissue, Riishede and Nielsen-
Kudsk demonstrated an elevated contractile velocity and frequency, but reduced maximal 
contractile amplitude with epinephrine144. Reduced contractile force was also found by 
Schiffmann et al, who showed depressed effects of epinephrine on isolated hearts at 28°C150. 
They reported that the negative effects of epinephrine during hypothermia was in close 
relation to intracellular Ca2+ concentrations150. In vivo studies on epinephrine administration 
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during hypothermia, demonstrated a possible negative effect on global hemodynamics98,145,151. 
Tveita and Sieck investigated the effects of hypothermia on dose-response of epinephrine in 
rat151. They demonstrated that a high dose of epinephrine (1.25 g/min) significantly elevated 
CO at 37°C, but the effects was diminished upon cooling to 33°C. This was not the case with 
a lowered dose, as 0.125 g/min improved CO and SV down to 30°C. Kondratiev et al. also 
found a depressive effect on CO and SV with 1 g bolus of epinephrine during rewarming 
from 15°C, while 0.1 g significantly elevated CO during and after rewarming145. Dietrichs et 
al. had similar findings during hypothermia and rewarming, but epinephrine elevated CO after 
successful rewarming, when animals went through the hypothermia and rewarming protocol 
without receiving epinephrine or other cardiovascular support98. In contrast to the highlighted 
studies, Cotten and Brown found a preserved contractile response to epinephrine in dogs 
cooled to 22°C. A 1 g/kg bolus injection at 22°C caused an 136% increase in cardiac 
contractile parameters152.  
 
The vascular response to epinephrine seems to be altered by hypothermia. Kondratiev et al, 
Tveita and Sieck, and Dietrichs et al. showed elevated MAP and SVR with low-dose 
epinephrine during hypothermia98,151. This is in sharp contrast to the vascular effects seen in 




The elevated -receptor sensitivity associated with hypothermia have significant 
physiological and hemodynamic consequences. Norepinephrine, is a potent -receptor 
agonist, commonly used as a vasopressor to maintain perfusion pressure in hemodynamic 
unstable patients during intensive care treatment. Cotten et. al demonstrated in an in vivo dog 
model that norepinephrine potentiated the contractile properties of the heart at 29°C. As with 
epinephrine, the beneficial effects diminished at higher concentrations. Further, both the 
negative and positive effects of norepinephrine on cardiac contractility are abolished by -
blockade, indicating that norepinephrine bind -receptors during hypothermia153.  
 
While norepinephrine has biphasic effects on cardiac contractility in dogs, Weiss et al. found 
a graded response to 0.2-5.0 g/kg/min of norepinephrine at 30°C, and although not 
significant, CO was depressed and SVR and MAP, elevated. After rewarming, norepinephrine 
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had a more beneficial profile, and, although not significant, provided graded elevation in CO 
and MAP, with little change in SVR154. In a similar model, Weiss et al., failed to demonstrate 
the same beneficial effects after rewarming. In more detail: 0.2 and 1.0 g/kg/min did 
improve CO insignificantly, 5 g/kg/min depressed CO significantly and increased MAP with 
no change in SVR155. 
 
It seems that the effects of norepinephrine during hypothermia is closely related to changes in 
-receptor affinity to norepinephrine and cause reduced CO and SVR, possibly through the 
negative effects on -receptor stimulation during hypothermia.  
 
5.4.2.2.3 Isoprenaline 
Riishede and Nielsen-Kudsk investigated the effects of isoprenaline down to 22°C. Here they 
demonstrated elevated contraction velocity (Emax and EC50), and heart rate (HR), in vitro. At 
low doses at 22°C isoprenaline provided elevated contraction amplitude, but high 
concentrations depressed contraction144. In isolated hearts cooled to 27°C Nakae et al. 
demonstrated that 1 nM isoprenaline improved contractile function as measured by dP/dTmax 
and developed LV pressure156.  
 
The improved contractile force by isoprenaline demonstrated in vitro, is not reproduced in 
hemodynamic in vivo studies of hypothermia and rewarming. Lauri fond no benefit of 
isoprenaline on CO at 25°C, a finding repeated after rewarming157. These findings resonated 
with data from Han et al. from hypothermic rats where only a high dose isoprenaline 
produced a small elevation in CO, with no alleviation of SVR. After rewarming the low doses 
of isoprenaline depressed CO, while the highest dose only improved CO by 10 %. 
Isoprenaline increased SVR at all concentrations after rewarming158. 
  
5.4.2.2.4 Dopamine and dobutamine 
Dopamine has been demonstrated to improve CO, also during hypothermia159. The findings 
resonate with Filseth et al. who found improved cardiac index (CI), HR, and reduced SVR 
with 8 and 16 g of dopamine at 32°C. At 25°C the same dopamine doses elevated HR, SVR 
improved, but caused no change in CI. Contrary to these findings, in a similar study, Roscher 
et al. found little benefit of dopamine (5g/12g) on CO and SVR at 32°C, despite a 
reduction in MAP and elevated HR. Riishede and Nielsen-Kudsk also investigated effects of 
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dobutamine on isolated rabbit hearts during cooling to 22°C. They found that dobutamine 
reduced amplitude of left ventricular force at 27°C, increased it at 22°C, but never to 
normothermic values. The same pattern was present for contraction velocity. As with 
epinephrine, high concentrations of dobutamine produced depression in force production144.  
 
In isolated guinea pig hearts, Rieg et al. found no significant change in inotropic force in 
response to increased concentration of dobutamine given at 34°C and 31°C160. In larger 
animal models English et al. demonstrated improved effects of dobutamine as dopamine in 
their study159: Improved hemodynamics during hypothermia.  
 
5.4.2.3 Milrinone 
Different from -receptor agonists, milrinone influences the pathway downstream from the -
receptor by inhibiting phsophodeesterase-3 (PDE3), an enzyme responsible for cAMP 
breakdown161. In normothermia, milrinone is demonstrated to reduce SVR by vasodilatation 
and elevate CO through increased cardiac contractility. During cooling, Tveita and Sieck 
demonstrated elevated CO and reduced SVR in rats pre-treated with milrinone162. Dietrichs et 
al. demonstrated the same beneficial effect when rats were treated with milrinone during 
rewarming from 3 hours of hypothermia163. The beneficial effects of milrinone on cardiac 
contractility during hypothermia has been questioned by investigators160. As neither of the 
experimental studies mentioned have measured cardiac contractility, it is possible that the 
beneficial effects of milrinone on post-hypothermic CO originates from LV afterload 
reduction. 
 
5.4.2.4 Levosimendan (LS) 
Unlike milrinone and -receptor agonists, LS works by elevating myofilament Ca2+ 
sensitivity in cardiomyocytes. In addition, it opens K+-channels in vascular smooth muscle, 
promoting vasodilatation. Lastly, at high cellular concentrations, LS also exhibit PDE3-
inhibitior properties, which together improve cardiomyocyte contractility and cause 
vasodilatation. The beneficial effects of LS on cardiac contractility seems to be preserved at 
31 and 34°C160. Further, in rat models of hypothermic cardioplegia and extracorporeal 
rewarming under simultaneous administration of LS, it seems to improve cardiac function 
after weaning from extracorporeal circulation164 
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5.4.2.5 Sodium nitroprusside (SNP) 
SNP, a nitric oxide donor, impose vasodilatation by promoting smooth muscle cGMP 
activation. In intensive care medicine SNP is used to ameliorate high blood pressure and 
afterload in critically ill heart failure patients165,166. While hemodynamic effects of SNP have 
been investigated extensively in the normothermic setting, few studies are available on its 
hemodynamic effects during hypothermia. In dogs cooled to 29°C, Morray et al. found 
improved CO and reduced SVR after SNP infusion following rewarming167.   
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6 Aims of thesis 
This thesis is motivated by an ambition to better understand the cardiovascular 
pathophysiology underlying HCD by adding new experimental research. Even more 
ambitious: to improve patient treatment and outcome based on this new information. If 
hypothermia exposure time is sufficiently long and the temperature deep enough, the 
cardiovascular state imposed is not reversed by rewarming, and the following physiological 
consequences are hemodynamic instability and reduced organ perfusion, and in turn organ 
damage and dysfunction. The hemodynamic instability calls upon challenging intensive care 
treatment, prolonged hospitalization, which unfortunately ends up in high patient mortality.  
 
This thesis will focus on and explore two key aspects associated with accidental hypothermia 
and rewarming; depressed cardiac contractility and elevated systemic vascular resistance. 
The thesis aims to answer three questions related to these two aspects:  
 
- Is hypothermia-induced contractile dysfunction ameliorated by increasing myocardial 
Ca2+-sensitization pharmacologically by LS?  
- Is the elevated vascular resistance during and after hypothermia a physiological 
compensation to the lowered cardiac output and perfusion pressure, or part of a 
hypothermia-induced pathophysiologic process on its own, leading to depressed 
cardiac function? 
- Is organ perfusion affected by pharmacological amelioration of HCD, or reducing 
systemic vascular resistance, or the combined impact of cardiac support and 
vasodilation during hypothermia and rewarming? 
 
To answer these questions, we utilized a rat model of accidental hypothermia designed to 
induce and study HCD. This thesis aimed at studying the combined impact of HCD and 
vascular function on organ blood flow. To do this we manipulated cardiac contractility and/or 
vascular resistance with either LS or SNP.  
 
6.1 Paper I 
The aim of this paper was to investigate how HCD is affected by the combined impact of 
increased Ca2+-sensitivity and PDE3-inhibition during hypothermia and rewarming. This was 
achieved with the administration of a high-dose LS in our experimental hypothermia rat 
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model of after 3 hours of exposure to 15°C. In addition, the study aspired to investigate the 
effects of PDE3-inhibition on cardiac troponin I phosphorylation, a known cellular 
mechanism associated with hypothermia-induced contractile dysfunction. 
 
6.2 Paper II 
The aim was to investigate if the elevated SVR associated with hypothermia and rewarming 
depresses cardiac function or not. An identical experimental rat model, as in paper I was 
utilized. To manipulate SVR in isolation, SNP was administered during the last hour of 
hypothermia and during rewarming. 
 
6.3 Paper III 
Paper III aimed to explore whether the improved cardiac function demonstrated by both LS 
and SNP after rewarming results in improved organ perfusion, oxygen delivery and oxygen 
consumption during rewarming from hypothermia. To achieve these aims we used a modified 




7 Summary of results 
7.1 Paper I  
This study focused on hemodynamic effects of elevating myofilament Ca2+ sensitization 
during rewarming to improve cardiac contractility and possibly ameliorate HCD. A high dose 
LS was used to achieve the proposed aim. Animals treated with LS regained pre-hypothermic 
contractility (PRSW) and CO. Further analysis showed that both increased SV and HR 
contributed to the elevated CO at 37°C after rewarming. LS also reduced SVR during 
hypothermia and rewarming. Placebo treated animals had depressed CO and PRSW, while 
SVR was significantly increased after rewarming at 37°C. 
 
7.1.1 Cooling 
When cooled from 37°C to 15°C, both hypothermic groups suffered a significant depression 
of hemodynamic function. MAP, CI, CO, dP/dTmax, end systolic pressure (ESP) and HR were 
all significantly depressed at 15°C, while SV, minimum rate of LV pressure change 
(dP/dTmin), SVR and the isovolumic relaxation constant (Tau) all increased. 
 
7.1.2 Rewarming 
After rewarming, under continuous LS or placebo infusion, hemodynamic function differed 
between the two groups. Treated with LS, the animals had improved CO, PRSW, dP/dTmax 
ESP, CI, SV, HR and SW after at 37°C after rewarming compared to placebo. In addition, 
while the placebo group presented evidence of rewarming shock (depressed CO, PRSW, CI, 
SV and SW) the LS treated animals regained pre-hypothermic baseline values for most 
hemodynamic variables.  
 
7.1.3 Normothermic control 
After 5 hours of normothermia, with the last 2 hours with continuous LS infusion, CO, HR, 
dP/dTmax, SV and SW were all increased compared to baseline.  
 
7.1.4 Phosphorylation of cTnI 
Western Blot data showed a significant increase in cTnI S23/24 phosphorylation in the LS 
treated group (0.28 ± 0.03) compared to placebo (0.16 ± 0.03) after rewarming.  
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7.1.5 Release of cTnI  
After rewarming at 37°C plasma cTnI was significantly different between the hypothermic 
groups and the normothermic control group (1.4 ± 0.4 ng/mL). No difference was, however, 
found between the two hypothermic groups receiving LS (8.2 ± 2.1 ng/mL) or placebo (14.6 ± 
4.6 ng/mL).  
 
7.2 Paper II 
This study aimed at separating the hemodynamic effects of pharmacologic vasodilatation 
during H/R by use of SNP infusion during rewarming. After rewarming, SNP-treated animals 
had lower SVR, MAP and EDP, and elevated CO compared to saline treated animals.  
 
7.2.1 Baseline and cooling 
At baseline no differences in hemodynamics were found between groups. After cooling to 
15°C all groups showed depression in CO, MAP, HR, EDP, and dP/dTmax, while SV, dP/dTmin 
and Tau were increased. 
 
7.2.2 After rewarming  
Within group comparisons: 
Both groups demonstrated depressed SV, CO and PRSW compared to baseline. The SNP 
treated group also had a reduced MAP and ESP, while the control group had elevated SVR.  
 
Between-group comparisons 
After rewarming SNP improved CO and SV, and reduced SVR, ESP and MAP compared to 
the control group. No difference in PRSW was found between the groups. 
 
7.3 Paper III 
This study aimed to investigate if the beneficial effects of LS and SNP on CO and SVR also 
affect OBF and oxygen delivery during rewarming. LS and SNP treated animals demonstrated 
elevated CBF in addition to CO and SV after rewarming. SNP also elevated myocardial and 
stomach blood flow, effects not seen in the LS group.  
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7.3.1 Baseline and cooling 
No difference was found in hemodynamic or blood-gas data between the three hypothermic 
groups at baseline. 
 
7.3.2 After rewarming   
With-group comparisons 
After rewarming, all three groups demonstrated reduced CO and MAP, while SV was reduced 
only in the control group when compared to their prehypothermic baseline values. Compared 
to normothermic baseline, SBG and KBF was reduced in all groups at both 30°C and 37°C 
Further, CBF in the control group and left side CBF in the control and LS groups was reduced 
as 30°C compared to normothermic baseline. After rewarming to 37°C SNP and  
 
Between-group comparisons 
After rewarming CO and SV were significantly increased and SVR reduced in the LS and 
SNP groups compared to control. LS also improved CO compared to SNP-treatment. At 
30°C, no significant difference was found in organ perfusion between the three groups. 
Following rewarming, SNP improved CBF, MBF, SBF and total OBF, compared to the 
control group, while LS only improved CBF. Lastly, LS elevated DO2 and VO2 compared to 




8 Methodological description and considerations 
8.1 Experimental animal model (I, II, III) 
All experiments utilized an in-vivo animal model. Male Wistar rats (250 – 350g) was 
obtained from Charles River, Inc (USA). The animals were quarantined for one week before 
use. Housing was in accordance with guidelines for accommodation and care of animals 
(article 5 of the European Convention for the Protection of Vertebrate Animals used for 
Experimental and Other Scientific Purposes, Strasbourg, 18.III.1986). The rats had a 
microbiological status according to the recommendation of the Federation of European 
Laboratory Animal Science Associations. The animals had ad libitum access to water and 
food and provided with toys and gnawing sticks. The experimental protocol was approved by 
the Norwegian Animal Research Authority and conducted accordingly.  
 
8.2 Anesthesia and analgesia (I, II, III) 
Pharmacological anesthesia and analgesia was used in all experiments. The animals received 
an intraperitoneal injection of pentobarbital (50 mg/kg) and fentanyl (0.05 mg/kg) to induce 
surgical anesthesia and analgesia. Depth of anesthesia was determined by level of arousal, 
reaction to toe-pinch method and sound. Once deeply sedated, intravenous access was 
attained by introduction of a small pediatric CVC gently placed in the right jugular vein and a 
continuous infusion of pentobarbital (7.5 mg/kg/h) and fentanyl (0.05 mg/kg/h) was started. 
Once hemodynamic parameters are available, anesthesia was adjusted based also on heart rate 
and mean arterial pressure. During hypothermia <30°C pharmacological anesthesia was 
suspended as cold-narcosis commence.   
 
It is well known that warm-blooded animals lose consciousness when cooled to lower 
temperatures168,169. The effectiveness of cold-narcosis has been compared to pharmacological 
anesthesia and indicators of cerebral metabolism and arousal is shown to be equally 
reduced170. Further, the pharmacodynamics and pharmacokinetic properties of anesthetics are 
affected by hypothermia. Clearance of pentobarbital is reduced by 50 % at 30°C and 67% at 
25°C, while pentobarbital effectiveness is only reduced with 25 %. Also, fentanyl clearance is 
reduced by hypothermia. However, no data exists of fentanyl effectiveness126. Thirdly, the 
depressive effects of pentobarbital combined with the negative effects of hypothermia on 
cardiovascular function prohibit the experiments to investigate spontaneous circulation at 
deep hypothermia. The sum total of these concerns presented, support the use of cold-narcosis 
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<30°C. During rewarming at 30°C, pharmacological anesthetics and analgesics was reinstated 
throughout all experiments. 
 
8.3 Temperature, cooling, hypothermia and rewarming (I, II, III) 
All animals where immobilized on a hollow aluminum surgical table. The table was circulated 
with hot or cold water. Core temperature was monitored with an esophageal (I, II) or aortic 
(III) thermocouple. Cooling and rewarming was achieved by adding ice or warm water and 
regulating the water bath thermostat. Once the animal reached 15°C core temperature, cooling 
was stopped and 4 (I, II) or 3 hours (III) hypothermia was initiated. Cooling and rewarming 
took on average 60 and 90 minutes, respectively. 
 
8.4 Respiratory support (I, II, III) 
Airways where secured by tracheostomy in all animals. None of the animals achieved apnea 
by fentanyl or pentobarbital and all had spontaneous respiration at the start of the 
experiments. In rats, hypothermia is associated with depressed respiratory function <24°C. 
When apnea occurred in the hypothermic animals, a rodent ventilator was connected, and 
mechanical ventilation commenced. All animals where ventilated with a frequency of 16-18 
breaths/min, a peak inspiratory pressure of 18 mmH2O and an inspiratory/expiratory rate of 
45%.  
 
8.4.1 Regulation of respiration by α or pH-stat in hypothermia 
Blood gas management in hypothermia is a much-debated topic as alterations in blood 
rheology increase the solubility of gases, and in turn affecting the acid-base equilibrium56. 
Blood pH increase with about 0.016 points for every °C of reduced temperature56,171. Two 
main schools have emerged management of ventilation and blood gas interpretation: α-stat 
and pH-stat methods. The pH-stat method aims to adjust arterial pCO2 and pH to temperature 
corrected values. This usually entail increased pCO2 and reduced pH by hypoventilation. α-
stat ignores the need for temperature correction of blood gas values, and ventilation is 
adjusted to pCO2 of 5.3 kPa and pH 7.4172-174. The physiological and clinical consequence of 
α and pH stat is that the relative hypoventilation caused by pH stat cause cerebral 
vasodilatation and increase CBF during hypothermia172. This has been confirmed in 
randomized human studies undergoing hypothermia during CPB175. The benefit of this 
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vasodilatation has been questioned during CPB as studies have demonstrated poor 
neurological outcome in pH-stat treated humans after hypothermic CPB175,176.  
 
In the included studies mechanical ventilation was adjusted just after cooling to 15°C. An 
arterial blood gas was obtained and analyzed with the α-stat method and ventilation adjusted 
accordingly. The α-stat method is the preferred method in clinical practice175,176. Further, 
paper III aim to investigate the effects of SNP and LS on CBF during hypothermia and 
rewarming. pH-stat influence CBF by hypercapnic vasodilatation during hypothermia, this 
could interfere with the wanted effects of SNP and LS on vascular resistance and changes in 
CBF. 
   
8.5 Pharmacological intervention with LS and SNP 
In all three papers pharmacological intervention was initiated 1 hour prior to rewarming from 
15°C.  
 
In Papers I and III LS was used in similar doses as in clinical studies 177. A bolus dose of 24 
g/kg/min was given the first 10 minutes, and then a continuing infusion of 0.6 g/kg/min 
during the remaining hypothermic and rewarming period. The rationale behind a high dose of 
LS was to make use of both the Ca2+ sensitizing and PDE3-inhibiting effects of LS.  
 
As the aim of Paper II was to investigate the effects of SVR on cardiac function, SNP was 
administered aimed at lowering SVR. As SVR was calculated in the post-experimental 
analysis, MAP was utilized as a surrogate. During rewarming, SNP was administered with the 
aim of reducing MAP by 30 %, compared to historic controls from Paper I and from a 
previous study from Dietrichs et al, in an identical model163. In a dose-finding study, it was 
identified that the standard 10 g/kg/min normothermic dose resulted in cardiac standstill. 
Accordingly, infusion was started with 0.6126 g/kg/min at 15°C. Upon rewarming the dose 
of SNP was continually elevated to meet target MAP. In Paper II the average dose after 
rewarming was 14 g/kg/min. In paper III SNP was applied in the same manner as in Paper 
II, however the average dose after rewarming was 8 g/kg/min.  
 
The effects of SNP have been demonstrated to be in close correlation to the hemodynamic 
situation and it was found that elevated CO and preload reduce the effect of a stable SNP 
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infusion 178. The fact that rewarming from hypothermia is a state of regained hemodynamic 
function might explain the need for a continued elevation of SNP during rewarming. Further, 
the discrepancy between SNP treatment in Papers II and III might be explained by the effects 
of microspheres on the general circulation. It is evident from the results that the hypothermic 
control group suffers hemodynamically after microsphere injection at 30°C, compared to its 
counterparts in Papers I and II. The depressed hemodynamic state might affect the needed 
SNP to maintain a lowered MAP during rewarming.   
  
8.6 Hemodynamic measurements 
8.6.1 Vascular pressure, pressure derivatives and heart rate  
8.6.1.1 Paper I, II 
Arterial pressure was obtained with a 22G fluid filled catheter in the left femoral artery. Mean 
arterial pressure (MAP) was calculated as (1/3 systolic pressure) + (2/3 diastolic pressure). 
LV pressure was acquired with a Millar conductance catheter (SPR-838, Millar Instruments 
Inc., Texas, USA).  
 
8.6.1.2 Paper III 
Arterial and LV pressure was both obtained with 22G fluid filled catheters. Arterial pressure 
was obtained from the left femoral artery, while LV pressure was provided through right 
carotid artery catheterization. MAP was calculated as (1/3 systolic pressure) + (2/3 diastolic 
pressure).  
 
8.6.2 Stroke volume (SV) and cardiac output (CO) 
8.6.2.1 Paper I, II 
Real-time LV volume was obtained with a miniaturized 2.0F conductance catheter placed in 
the left ventricle, through the right carotid artery (SPR-838, Millar Instruments Inc., 
Texas)179. The catheter is placed as shown in Fig 1 and consists of one manometer and four 
electrodes (E1-E4). A constant current of low-amplitude high frequency is applied to the outer 
most electrodes, creating a small electrical field. The difference is voltage measured between 
E2-E3 depend on the conducting properties of the medium the electrical field passes through 
and is proportional to the volume of the same medium. As the electrical field is larger than the 
ventricular space during contraction, both the ventricular volume and the overlapping cardiac 
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muscle is included in the volume calculation. The result is an overestimated end-diastolic and 
end-systolic volume. To identify the ventricular volume, calibration is necessary179.  
 
Calibration can be achieved by a hypertonic saline (30 %) method (parallel conduction). This 
is done with 2-3, 40 L, saline injections before recording179,180. In the presented rat model, 
recordings were performed at 37, 32, 28, 24, 20 and 15°C during cooling and rewarming. 
Hypothermia is associated with large rheological and cardiac changes, affecting conductance 
and ventricular volume. This entail that hypertonic saline calibration has to be performed 
prior to all recordings. This would cause an unphysiological sodium load, possibly harmful to 
the hypothermic rat. 
 
We used the second option of ex-vivo calibration with cuvettes with known volumes179. 
Temperature calibration was preformed ex-vivo in an isolated cuvette with known diameters 
(2–7 mm) filled with heparin-treated blood20,181. The four-electrode Millar catheter (SPR-838) 
was inserted in the cuvette and volume was calculated using the following formula: V = πr2L, 
where r is the radius of the cuvette and L is the distance between catheter electrodes (E2 – 
E3). The cuvette was then lowered in a temperature regulated water and cooled to 15°C. The 
temperature specific measurements (37, 32, 28, 24, 20 and 15°C) were corrected using the 
cuvette calibration method described. CO was automatically calculated by LabChart 8. 
Calibration was applied just prior to analysis.  
 
While cuvette calibration helps to identify the linear relationship between conductance and 
volume at different temperatures, there is still difficulty to accurately true EDV and ESV. 
While a disadvantage, it does not prevent the studies to determine stroke volume as this is 
calculated by subtracting EDV with ESV. Because of the linear relationship between 
resistance and volume any change in blood volume during the heart cycle can be 
determined179. Further, the methodological review from Burkhoff et al. referred to a CO of 41 
– 60 in normal rats. While 10 mL/min higher, the animals described are up to 150g heavier. 
These comparisons give confidence to trust that the SV and CO data provided by the method 




8.6.2.2 Paper III 
The aim of Paper III was to investigate how regional blood flow during rewarming is affected 
by pharmacological manipulation of vascular resistance. To achieve this a microsphere 
technique was used to measure regional blood flow. Since the microspheres had to be 
introduced directly in the LV, the conductance catheter method was unsuitable. Therefore, 
CO was with thermodilution method. Thermodilusion is well studied in small rodent models 
and have been utilized in an identical rat model43,145. Due to technical difficulties, Kondratiev, 
was not able to produce viable measurements below 20°C. In the presented paper (III), 
improved equipment and analyzing tools provided reliable measurements even at 15°C. It 
should be noted that thermodilution in small animals, and at low flow, could overestimate CO 
due to a higher heat diffusion182,183. 
 
At 37, 30, 22 and 15°C, injections were performed in triplets and an average of all three was 
calculated. Before the measurements were performed, cooling or rewarming was halted to the 
point where the animals core temperature stabilized. 0.15 mL precooled (5°C) saline was 
rapidly injected directly in the right atrium. Changes in temperature was detected by a 
thermocouple placed in the aortic arch and thermodilution curves (fig 2) was analyzed and 
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recorded with LabChart 8. This provided direct CO measurements. CO and HR were used to 




8.6.3 Contractility (I, II) 
Cardiac contractility is the hearts ability to produce force. Contractility is difficult to measure, 
as many hemodynamic variables is influenced by the physiological state, such as preload, 
afterload and heart rate. Investigators have aimed to find variables reflecting contractility 
independent of extra cardiac influences. In vitro, total force produced, maximum tension and 
time to peak is used as contractile measurement in isolated muscle strips. In vivo, these 
measurements are impossible to acquire. Max ventricular pressure, dP/dTmax and SW are all 
dependent on either heart rate, preload and afterload179. To account for this, preload 
independent measurement has been developed. End systolic-pressure volume relationship 
(ESPVR) was first described by Sagawa et al. in 1977 and PRSW was proposed as a stronger 
indicatory of cardiac contractility by Glower et al. in 1985184,185. Glower et al. demonstrated 
that the relationship between SW and EDV is more linear and afterload independent than 
ESPVR. Lastly, a mathematical consequence of PRSW is that it independent of cardiac size, 




In Paper I and II PRSW was used as a preload-independent measurement of contractility to 
assess cardiac function before and after hypothermia. PRSW was obtained by external vena 
cava occlusions in triplets at baseline and after successful rewarming as compromised 
hemodynamics prohibits vena cava occlusions during hypothermia. PRSW was calculated by 
LabChart 8. The process is exemplified and illustrated in the figure below. 
 
PRSW was chosen as a favorable contractile parameter mainly as Gower et al discussed in 
their paper, as the relationship between SW and EDV is more linear than the ESPVR. But 
also due to limitations with our model to acquire a reliable ESP. A reoccurring challenge is 
that that the manometer is touching the ventricular wall during end systole. This create a 
“devil horn” on the cyclic pressure volume loops. During stable hemodynamic recording, 
these artifacts are ameliorated by catheter manipulation. However, the dynamic changes 
during vena cava occlusions can displace the catheter and the manometer in some cases touch 
the ventricle wall and create “devil horns”. Therefore, ESP and ESPVR is unreliable in the 
presented models. PRSW is however calculated independent of ESP by LabChart 8, as SW is 
calculated by the geometrical areal of each pressure-volume loop. The development of “devil 
horns” do potentially affect this calculation, but only minimally. PRSW is therefore a much 





8.6.4 Regional blood flow (III) 
A stable-isotope labeled microspheres (Biopal, Inc) technique was applied to investigate 
regional blood flow186. 0.5 ml of 125 000 microspheres (250 000/mL) was injected in to the 
LV. (BioPal, Mi, USA) Simultaneously 0.5mL arterial blood was sampled from the femoral 
artery at a rate of 0.5 mL/min19,187. Data was obtained at 30°C and 37°C during rewarming 
from hypothermia and at 37°C baseline, and at experimental endpoint in the normothermic 
animals. After ended experiments biopsies was collected from the brain, heart, liver, kidneys, 
ventricle, intestine, muscle and skin and weighed. The samples were then freeze-dried and 
shipped to BioPal (MI, USA) for analysis. Organ blood flow was later calculated by 
normalizing organ microsphere concentration [disintegration per minute (dpm) / g] with the 
microsphere concentration of the 0.5 ml/min reference sample (dpm / mL / min)186. Total 






8.7 Biochemical analysis  
8.7.1 Blood gas analysis and calculation of oxygen content (III) 
In paper III arterial blood gas was obtained at 37°C baseline, 15°C at the start of hypothermia, 
and at 30°C and 37°C during rewarming. A venous blood gas was obtained only after 
rewarming at 37°C. The blood was analyzed with no temperature correction applied 
(Rapidlab 800, Chiron Diagnostics, USA). The blood was analyzed for pO2, pCO2, oxygen 
saturation (SO2), pH, Hemoglobin (Hb), Hematocrit (Hct) and lactate. HCO3- and base excess 
was automatically calculated based on the measured data. Arterial and venous blood oxygen 
content (CaO2 and CvO2), oxygen delivery (DO2) and oxygen consumption (VO2) was 
calculated with the following formulas: CaO2 and CvO2 = (Hb x 1,34 x SO2 / 100) + (pO2 x 
0.0031 x 7.5), DO2 = CaO2 x CO and VO2 = CO x (CaO2-CvO2)188.  
 
8.7.2 Cardiac troponin I phosphorylation (I) 
After successful rewarming, the hearts were isolated and flash-frozen in liquid nitrogen. 
Phosphorylation levels on cTnI sites Ser23/24 were investigated using Western blot20. 
Antibodies targeting either total cTnI (Fitzgerald) or phosphorylated cTnI at Ser23/24 (Cell 
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Signal) was used. The amount of phosphorylation is measured as phosphorylation rate 
(density of phosphorylated Ser23/24-cTnI divided by total cTnI). 
 
8.7.3 Cardiac troponin I release (I) 
After experiments were completed, arterial blood was sampled from the left femoral artery. 
Blood was centrifuged, and the plasma extracted from the tubes. Plasma-cTnI was then 
analyzed, using a high sensitivity rat cTnI ELISA kit (Life Diagnostics, Inc., West Chester, 
PA, USA.)  
 
8.8 Statistical models 
8.8.1 Hemodynamic data 
All statistical analyses were done in SigmaPlot 13 (USA). Before any statistical test were run, 
data distribution was investigated for normality using Shapiro-Wilks test, if rejected (< 0.05) 
non-parametric ANOVA on ranks was performed. Hemodynamic development between with-
in each group was compared with a repeated measurement one-way ANOVA. If the H0 was 
rejected (p< 0.05) a Dunnett’s post-hoc test was performed as against pre-hypothermic 
control-levels (I, II, III). In-group change in PRSW was analyzed with a paired T-test (I, II). 
Between-group comparison at each time-point was done with a student T-test was preformed 
(I, II). In paper III, between-group comparison was done with a one-way ANOVA, if the H0 
was rejected, a Tukey post-hoc test was performed. Statistical significance was accepted if p 
<0.05. All results are presented as mean (I, II, II) +/- SEM (I, II) and SD (III). 
 
8.8.2 Biochemical data 
The cTnI-release data failed the Shapiro-Wilks test (I) between groups were analyzed using 
one-way repeated measures ANOVA on ranks. 
 
8.8.3 Western Blot analysis  
Data was analyzed with a one-way ANOVA, with a Tukey post hoc test. 
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9 General discussion 
9.1 Hypothermia, cardiac dysfunction and elevation of vascular resistance  
The presented studies (I, II, III) demonstrate a continuously depressed cardiac function and 
elevated SVR during hypothermia. In the hypothermia control groups, across the studies, the 
continued depression of SV, CO and contractility and elevation of SVR was present after 
rewarming. This resonates with previous investigations on the hemodynamic consequence of 
hypothermia and rewarming20,163,188,189. The intervention studies (I, II, III) further show the 
beneficial effects of both LS and SNP on SV, CO and SVR. Further, LS improved CO and 
SV superiorly in all three studies, while SNP lowered SVR more than LS, independently of 
measuring technique. Lastly, only LS elevated cardiac contractility after rewarming, as shown 
by improved PRSW and LV dP/dTmax (I, II).  
 
Multiple studies have attempted to improve cardiac contractility and hemodynamic function 
during hypothermia by stimulating the -receptor98,145,181,190. These studies all show little 
beneficial effects on the hemodynamic situation and a narrowed therapeutic window of -
agonists at low temperatures. Unlike direct adrenergic agonists, LS promote cardiac 
contractility independent of the -adrenergic axis. LS increase contractility by elevation of 
Ca2+-sensitivity of troponin C, promoting actin-myosin binding191,192. We here demonstrate 
that the therapeutic window of LS is preserved at low temperatures and improve CO and 
dP/dTmax during rewarming from 20°C. This resonate with clinical and experimental animal 
studies, with CPB, on the effects of LS at hypothermic temperatures164,193.  
 
At elevated concentrations, LS also promote PDE3-inhibition192, preventing cAMP 
breakdown and indirectly promoting the -adrenergic pathway. The cAMP-pathway is 
important in regulation of Ca2+-handling by phosphorylation of phospholamban, regulating 
the sarcoplasmic reticulum Ca2+-ATPase53. It is possible that the beneficial effects of 
milrinone on cardiac function in the rewarming scenario, like also in part by LS, is due to 
improved cardiac Ca2+-handling. In Paper I we show elevated troponin I phosphorylation with 
LS. This is an indication that LS elevate activity in the cAMP and PKA pathway67. It has been 
speculated that elevated Ser23/24 phosphorylation is contributing to contractile dysfunction 
during hypothermia as Ser23/24 phosphorylation is associated with lowered Ca2+ sensitivity 
20,69. However, it is likely that the beneficial effects of LS on Ca2+-sensitivity by directly 
binding to the c-terminal end of troponin I override the negative effects of Ser23/24 on Ca2+ 
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sensitivity. In separate studies, Dietrichs and Tveita  demonstrated the beneficial effects of 
milrinone, a selective PDE3-inhibitor on cardiac function during hypothermia and 
rewarming162,163. 
 
Elevation of SVR during and after hypothermia have been described in early 
investigations22,77. The presented studies (I, II, III) show that both LS and SNP lower SVR 
during and after rewarming. SNP lowered SVR superiorly to LS in all three studies. SNP has 
no documented direct effects on inotropic function, as also supported by finding a reduced 
PRSW after rewarming in our study. The likely explanation to our findings is that SNP 
ameliorated CO by reducing LV afterload, by systemic vasodilatation.  
 
In early investigations of hypothermia and rewarming the elevated SVR was explained by 
increased viscosity22,77. From our experiment (III) we observe that the post-hypothermic heart 
has to struggles against an elevated afterload, but by introducing SNP during rewarming 
systemic vasodilatation is achieved and provides relief to the failing heart. The presented 
studies do not provide an answer to the mechanisms underlying the elevated SVR but indicate 
that a vascular myogenic component, responsive to SNP, is of significant importance. As 
highlighted in the introduction, investigators have identified changes in RAAS and 
catecholamine levels58,62,64,88, vascular -receptor super-sensitization and altered receptor 
composition90,98,144,145,147,148, endothelial dysfunction and smooth muscle cell 
dysregulation101,102.   
 
9.2 Organ blood perfusion, cardiac output and cardiovascular autoregulation in 
hypothermia 
Hypothermia depress organ perfusion. Depending on the depth and length of hypothermia, 
this continues even after rewarming19,81. In this study (III) we show a reduction in CBF, MBF, 
SBF and KBF in non-treated animals during and after rewarming from 3 hours at 15°C. These 
findings are consistent with similar experimental models19. At the same time, we demonstrate 
a reduction in CO and elevated SVR. In concordance to Paper I and II, LS elevated CO 
superiorly to SNP in Paper III. While SNP elevated CBF, MBF, SBF and total OBF 
compared to the control group, LS only elevated CBF. These findings are interesting as it 
seems that the available increase in CO produced by LS do no translate into elevated OBF. In 
contrast, SNP improved organ perfusion with only a minor elevation in CO. This indicates 
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that other mechanisms than just the availability of blood flow limits organ perfusion in the 
rewarming scenario.  
 
9.2.1 Cerebral blood flow (CBF)  
In animal experiments with spontaneous circulation and CPB, cerebral oxygen consumption 
(CMRO2) has been demonstrated to be reduced during hypothermia194-196. Further, down to 
28°C CBF/CMRO2 ratio is unchanged as CBF is decreased proportionally to CMRO2. In pigs 
cooled on CPB, Ehrlich et al. found the ratio to be doubled after cooling to 18°C195, this 
finding is mirrored in dog experiments175,197,198. This increased mismatch between CBF and 
CMRO2 has been interpreted as a failure in cerebral autoregulation172. The investigation by 
Ehrlich also indicted that cerebral metabolism is not limited by the lowered CBF, as 
hypercapnia-induced increase in CBF failed to elevate CMRO2 at 18°C195.  
 
After rewarming pigs following 2,5 hours hypothermic CPB, Steen et al. found a continued 
reduction in CMRO2, as well as reduced CBF199. On the contrary, Michenfelder, using an 
almost identical model, restored CMRO2 to baseline values, with a continuation in CBF 
depression after rewarming197,198. Michenfelder argued that the findings of Steen et al. were 
the result of pharmacologic depression of cerebral metabolism caused by high doses of 
thiopental. Like Michenfelder, also Murkin found normalization of CMRO2 in humans, after 
rewarming from hypothermic CPB175.  
 
It is evident that the highlighted findings are not directly comparable to findings in our model, 
as all studies are based on using CPB in large animals and in man. However, these data show 
that the effects of temperature on cerebral metabolism are fairly linear and that CMRO2 is 
normalized after rewarming. Studies show the detrimental effects of hypothermia and 
rewarming on CBF 19,197,198. It  is therefore likely that CBF/CMRO2 ratio is lowered after 
hypothermia, like Michenfelder and Steen demonstrated in their dogs, irrespective if on  CPB 
or with spontaneous circulation87,197,198.  
 
Clinical studies on the neurological outcome in patients treated with hypothermic CPB 
applying the pH-stat vs. the α-stat strategy have shown that pH-stat may induce cerebral 
vasodilatation and elevation of CBF during hypothermia. However, it causes a worse 
neurological outcome than α -stat. The investigators attributed this to a higher load of 
microemboli from particles and gas bubbles during CPB200,201. The pH-stat strategy aims at 
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regulating pCO2 during hypothermia, and as rewarming progress, the relative hypercapnia 
induced cerebrovascular vasodilatation lost. At the same time as the CBF/CMRO2 ratio is 
shifted. The investigations are therefore not able to detect a potentially beneficial effect of 
continued cerebrovascular vasodilatation after rewarming.  
 
Study III is limited to investigate whether the elevated CBF induced by SNP or LS has 
benefits to the animal outside the measured hemodynamic improvements. However, the 
presented body of evidence suggest that the rewarmed brain is vulnerable to low CBF and 
might indicate that SNP and LS may secure cerebral oxygen delivery to prevent further 
neurological damage.  
 
Autonomic regulation of cerebral flow seems to be maintained at temperatures down to 28°C. 
Below this, a state of hyperperfusion occur, and investigators have interpreted this as failed 
autoregulation172,195. During rewarming, however, the growing discrepancy between CRMO2 
and CBF indicate hypoperfusion and a continued failure in autoregulation. This is supported 
by findings of elevated cerebral vascular resistance after rewarming, as well as a lowered 
CBF, despite normal perfusion pressure given by the  CPB202,203. In models of spontaneous 
circulation, as the one presented (III), the reduction in CO cannot explain the reduced CBF, 
and an elevation of CO by LS do not result in fully restored CBF. This might indicate that the 
cerebral vascular regulatory system is affected by hypothermia and rewarming, and the 
beneficial effects of SNP suggest cerebrovascular vasoconstriction.  
 
9.2.2 Myocardial blood flow 
Coronary perfusion pressure depends on aortic pressure and coronary vascular resistance204. 
During systole, the intraventricular pressure prevents perfusion of the myocardium, as this 
constricts the coronary capillaries. Further, the coronary vasculature is sensitive to the 
metabolic demand of the heart, and a strong relationship has been found between MBF, 
cardiac oxygen consumption (MVO2) and tissue oxygen content. More minor regulatory 
mechanisms are neurohormonal control and vasoactive responses to changes in local blood 
biochemistry. Berne approximated that changes in MVO2 may cause five to ten-fold changes 
in MBF, while the latter only produce changes between 40-50%73,204,205.   
 
Investigators have demonstrated a reduction in MBF during hypothermia with spontaneous 
circulation19,81,205-207. Further, Berne showed that the coronary regulation of flow is altered in 
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hypothermia. As the relative reduction in MBF is lower that the change in aortic perfusion 
pressure, he argued that the coronary vessel is relatively vasodilated205,208. He further stated 
that the effects of hypothermia on coronary smooth muscle is relaxation, and that this is the 
main explanation to the vasodilatation and high MBF/MVO2-ratio205,208.  
 
In concordance with previous studies, study III also shows a reduced MBF during and after 
rewarming19. MBF regulation after rewarming is not fully elucidated. In an in vivo study on 
coronary response to vasodilatation during hypothermia, Tveita et al. found that the coronary 
vasculature has reduced sensitivity to endothelium dependent and independent vasodilatation, 
which was normalized after rewarming100. This is a possible indication of functioning 
vascular regulation. While the actual study (III) made no attempts to investigate endothelium 
dependent vasodilatation, it however showed that SNP induced extensive vasodilation of the 
coronary circulation. Like during normothermia, LS turned out unable to elevate MBF in the 
rewarming scenario, despite a higher aortic perfusion pressure and higher CO209. As (for) with 
the cerebral circulation, this indicate that coronary resistance is an important factor in post-
hypothermic organ hypoperfusion. 
 
Further, the data show that LS improved cardiac contractility with no elevation in MBF. This 
is important as the increased contractility should come at an cost in O2 expenditure210,211. As 
this model was not equipped to measure MVO2 and cardiac oxygen extraction, this is only 
speculations. However, the findings indicate that the cardiac DO2 sufficiently supplied MVO2, 
also in the case of incrased contractility. This mirrors the ideas of Kondratiev et al.  that 
oxygen supply is not a limiting factor for cardiac function in the rewarming scenario188.  
 
9.2.3 Renal blood flow 
Regulation of RBF is controlled by two main vascular mechanisms, a fast-myogenic response 
and a slowed feedback mechanism dependent on glomerular filtration rate (GFR) and urine 
production. Both mechanisms regulate RBF by afferent vasoconstriction/dilatation, while the 
slowed feedback mechanisms also regulate RBF indirectly through changes in blood volume 
and perfusion pressure through the RAAS. The slowed feedback mechanism is also connected 
to renal function and metabolism73,212.  
  
In rats with spontaneous circulation, RBF is reduced by 40% at 28°C213.  Identical findings 
were made by Hong, Tveita, Anzai and Levy in different models of experimental hypothermia 
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investigating renal blood flow19,81,214,215. Broman and Levy independently argued that the 
reduced RBF was a consequence of elevated renal vascular resistance. Renal metabolism and 
function also demise during cooling. GFR is reduced, and both renal reabsorption of sodium, 
and active excretion are reduced. The consequence is increased water loss, recognized as the 
well documented elevated urine production during hypothermia213,215,216.  
  
After rewarming from 28°C, Broman found complete restoration of RBF and renal 
function213. This stand in contrast to the findings in paper III, as well as multiple other 
investigators19,81,217. Bromans experiment did not prolong the hypothermic period, and the 
discrepancy in temperature, might explain the findings213. In dogs, Karim and Patton 
independently demonstrated depressed GFR and RBF after rewarming from 25°C216,217.  
 
Investigators argue that the reduced RBF and GFR after rewarming is due to maintained 
vasoconstriction. In a second study, Broman concluded that circulating catecholamines or 
efferent renal sympathetic activation did not play a role and pointed to other unidentified 
mechanisms.  Karim highlight the elevated  RAAS hormones have been demonstrated to 
increase during hypothermia217,218.   
 
The presented data show that neither SNP, nor LS improved RBF after rewarming, despite 
elevation of CO in response to both these substances. Interestingly, Broome et al. investigated 
the effects of SNP on RBF and SBF during angiotensin II-induced vasoconstriction219. They 
found that SNP failed to alleviate RBF, but normalized SBF. They interpreted this as 
evidence of a powerful renal vasoconstrictive effect of ATII. In paper III, the same 
discoveries where made. While not conclusive, this might indicate that RAAS, and especially 
angiotensin II, plays an important part in vascular dysfunction during and after rewarming. 
However, in a previous experiment exposing the same model to a similar H/R protocol as in 
experiment III, we reported changes in renal morphology after rewarming similar to those of 
acute tubular necrosis. This finding may well correspond with the present finding of a reduced 
RBF after rewarming220.   
 
9.3 Translational value, and future research 
The use of small animal models to demonstrate and investigate physiological and 
pathophysiological processes has provided much new knowledge and expanded medical and 
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physiological research. However, direct translation between species and implementation to 
clinical practice must be done with great caution.  
 
The presented model is designed to induce and investigate effects of deep hypothermia on 
cardiovascular function. To do this the rat model was chosen as this species is able to 
maintain spontaneous circulation at temperatures down to 13˚C. Some of the methodological 
limitations are previously highlighted, but the physiological differences between species has 
not been discussed. In light of the obvious limitations and difference in species I do believe 
that the presented and applied model is able to answer the proposed questions and produce 
new reproducible knowledge about physiology under hypothermic condition. This model has 
demonstrated to reproduce similar pathophysiological changes of hypothermia and rewarming 
as described in other species, including humans. I therefore believe that the 
pathophysiological and pharmaceutical discoveries presented here are relevant and can be 
applied in larger models exposed to experimental hypothermia and rewarming, also in 
combination with cardiac arrest or active rewarming techniques.  
 
To further explore the therapeutic possibilities of LS and SNP in the rewarming scenario the 
next natural project is to move to a large animal model. As severely hypothermic and 
hemodynamically unstable patents are rewarmed by CPB or ECMO, a study on the effects of 
SNP and LS co-treatment on cardiac function and organ perfusion during experimental 
hypothermia and ECMO rewarming would be very interesting, especially with focus on 
weaning from extracorporeal circulatory support.  
 
9.4 Final conclusions 
The overreaching objective of this thesis was to investigate the relationship between cardiac -
and vascular function in a model of accidental hypothermia and rewarming. We therefor 
studied effects of levosimendan and sodium nitroprusside on cardiac function and on organ 
blood flow. The main conclusions based on the experimental results are: 
- Levosimendan improved CO after rewarming from hypothermia. This is attributable 
to increased cardiac contractility as demonstrated by elevated PRSW, and possibly to 
systemic vasodilatation. This demonstrates that hypothermia-induced cardiac 
dysfunction is partly reversible by means of a Ca2+ sensitizer. 
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- Having no effect on cardiac contractility after rewarming, SNP reduced SVR and 
elevated CO. We interpret this as follows; the post-hypothermic elevation of SVR 
limits cardiac performance, a mechanism which appears to be an important 
pathophysiologic element in the ensuing hypothermia-induced cardiac dysfunction 
 
- Organ perfusion was improved both by LS and the vasodilator SNP. SNP improved 
organ blood flow more than LS, despite a more modest elevation of CO. We interpret 
this as follows: Hypothermia-induced persistent elevation of vascular resistance leads 
to a reduced organ blood flow and a compromised cardiac function during rewarming. 
Further, the literature and presented studies suggest impaired autoregulation of organ 
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Calcium sensitizera b s t r a c t
Background: Previous research aimed at ameliorating hypothermia-induced cardiac dysfunction has
shown that inotropic drugs, that stimulate the cAMP, – PKA pathway via the sarcolemmal b-receptor,
have a decreased inotropic effect during hypothermia. We therefore wanted to test whether levosimen-
dan, a calcium sensitizer and dose-dependent phosphodiesterase 3 (PDE3) inhibitor, is able to elevate
stroke volume during rewarming from experimental hypothermia.
Methods: A rat model designed for circulatory studies during experimental hypothermia (4 h at 15 C)
and rewarming was used. The following three groups were included: (1) A normothermic group receiving
levosimendan, (2) a hypothermic group receiving levosimendan the last hour of stable hypothermia and
during rewarming, and (3) a hypothermic placebo control group. Hemodynamic variables were moni-
tored using a Millar conductance catheter in the left ventricle (LV), and a pressure transducer connected
to the left femoral artery. In order to investigate the level of PKA stimulation by PDE3 inhibition, myocar-
dial Ser23/24-cTnI phosphorylation was measured using Western-blot.
Results: After rewarming, stroke volume (SV), cardiac output (CO) and preload recruitable stroke work
(PRSW) were restored to within pre-hypothermic values in the levosimendan-treated animals. Compared
to the placebo group after rewarming, SV, CO, PRSW, as well as levels of Ser23/24-cTnI phosphorylation,
were significantly higher in the levosimendan-treated animals.
Conclusion: The present data shows that levosimendan ameliorates hypothermia-induced systolic dys-
function by elevating SV during rewarming from 15 C. Inotropic treatment during rewarming from
hypothermia in the present rat model is therefore better achieved through calcium sensitizing and
PDE3 inhibition, than b-receptor stimulation.
 2014 Elsevier Inc. All rights reserved.Introduction
Case-reports show that the human body can survive core tem-
peratures down to 13.7 C and up to 7 h of hypothermic cardiac
arrest [6,18]. Although survival is reported in such extreme situa-
tions, the mortality rate of accidental hypothermia is still described
to be between 29% [30] and 80% [17]. A report from Melbourne
showed that 13% of patients admitted to the emergency depart-
ment had a core temperature below 35 C. This patient group
had a threefold independent risk of death [11]. The complications
related to hypothermia is also acknowledged in surgical proce-
dures, as use of therapeutic hypothermia during aortic surgery is
related to increased need for inotropic support [2]. Thus, finding
optimal strategies for treatment of patients subjected to therapeu-
tic hypothermia and victims of accidental hypothermia is essential.
E.S. Dietrichs et al. / Cryobiology 69 (2014) 402–410 403Contributing to the high mortality of accidental hypothermia,
rewarming is often complicated by cardiac dysfunction. Although
this condition [29] was described as early as in 1826 by the French
surgeon Moricheau-Beaupré [7], the pathophysiology behind it is
not yet completely understood. Animal studies show that hypo-
thermia-induced cardiac dysfunction is related to calcium overload
[33], but not oxygen deficiency [13]. Further studies have tested
inotropic drugs in order to counteract development of this condi-
tion. Among tested drugs are the b-agonists epinephrine and iso-
proterenol, which at normal core temperatures mediate positive
inotropic effects by stimulating the cyclic AMP (cAMP), – protein
kinase A (PKA) pathway. Remarkably, preclinical studies demon-
strate diminished or adverse cardiovascular effects of these drugs
when applied to treat hypothermia-induced cardiac dysfunction.
Rather than giving positive inotropic effect, increased cardiac after-
load, and lack of elevated SV dominated the hemodynamic
response to b-agonists in hypothermic animals [14,12,8,28].
The calcium sensitizer levosimendan has potential in this
setting. Acting through binding of cardiac troponin C (cTnC), levo-
simendan provides inotropic effect by stabilizing the calcium–
cTnC–cTnI complex. In this way, levosimendan accelerates the
cross-binding between actin and myosin [20]. In high concentra-
tions levosimendan also function as a PDE3 inhibitor [25,3]. Inhibi-
tion of PDE3 will however increase cAMP and PKA, and thus induce
Ser23/24-phosphorylation of cTnI. In a previous study carried out
in our lab, we showed that contractile dysfunction after rewarming
was related to increase of PKA-induced Ser23/24-cTnI phosphory-
lation [9], known to reduce myofilament calcium-sensitivity [19].
In contrast to epinephrine [28], which only had positive inotropic
effect above 28 C, administration of the PDE3 inhibitor milrinone
demonstrated positive inotropic effect also during cooling below
28 C [27]. Thus, in spite of the assumed increase in PKA-mediated
Ser23/24-cTnI phosphorylation, PDE3 inhibition shows favorable
effects on LV cardiac function at low core temperatures. According
to clinical studies [16] we therefore wanted to test a high dose of
levosimendan (bolus: 24 lg/kg, continuing infusion: 0.6 lg/kg/
min) to make use of the combined effect of calcium sensitizing
and PDE3 inhibition and explore whether this has potential to
ameliorate hypothermia-induced cardiac dysfunction. To achieve
this, we tested the effect of levosimendan on cardiac function dur-
ing rewarming from 15 C, using our rat model designed for hemo-
dynamic measurements where spontaneous cardiac activity is
maintained at all temperatures [33,13,14,12,8,28].Materials and methods
Male Wistar rats (270–346 g) were used. The animals were pro-
vided by Charles River and quarantined for 1 week on arrival.
Housing was provided in accordance with guidelines for accommo-
dation and care of animals (article 5 of the European Convention
for the Protection of Vertebrate Animals used for Experimental
and Other Scientific Purposes, Strasbourg, 18.III.1986). The rats
had a microbiological status according to the recommendation of
the Federation of European Laboratory Animal Science Associa-
tions. Free access to food and water was permitted at all times.
The experimental protocol was approved by the Norwegian Animal
Research Authority and conducted accordingly.Fig. 1. Temperature profile of the experiments in rats assigned to either of the
hypothermic groups, showing the cooling (37–15 C) and rewarming (15–37 C)
rates and the stable hypothermic period (15 C): Values are mean ± SEM.Anesthesia
Anesthesia was introduced intraperitoneally by pentobarbital
sodium (55 mg/kg) and fentanyl (50 lg/kg), followed by a continu-
ous infusion of 7.5 mg/kg/h pentobarbital sodium and 50 lg/kg/h
fentanyl through an intravenous line in the right jugular vein,
extended to the right auricle. The anesthesia infusion wasmaintained at all hours in normothermic animals. In hypothermic
animals, infusion was terminated at 30 C during cooling and
restarted at the same temperature during rewarming, due to hypo-
thermia-induced anesthesia and reduced drug metabolism. The
animals were monitored by toe-pinch for any sign of discomfort
so that additional anesthesia could be provided if necessary. This
is a well-established method for testing the effects of analgesic
drugs in rodents and has been extensively tested in rats [4]. Toe
pinch has been used for this purpose in all studies in the present
model [33,13,14,12,8,28].
Respiratory support
Animals were placed on the operating table in a supine position.
The trachea was opened, and a tracheal tube inserted. All animals
had spontaneous and sufficient ventilation at core temperatures
>20 C. Below 20 C, ventilation was achieved by a volume-con-
trolled small-animal respirator (New England rodent ventilator,
model 141, New England Instruments, Medway, MA) using room
air. Normoventilation was achieved through adjusting ventilation
in accordance with blood gas analyzes (ABL 800 blood gas analyzer,
Bergmann diagnostika). During controlled ventilation, the alpha-
stat strategy was followed.
Core cooling and rewarming
Animals were cooled and rewarmed by circulating cold or warm
water (Thermo stated water bath type RTE-110, Neslab Instru-
ments, Newington, NH) through an U-shaped polyethylene tube
placed in the lower bowel. The tube was inserted gently to avoid
harm of the intestine. In addition, the double-layered operating
table made of hollow aluminum was circulated by temperature-
adjusted water. Core temperature was continuously monitored
using a thermocouple wire, positioned in the lowest part of the
esophagus connected to a thermocouple controller (Thermalert
Th-5, Bailey Instruments). Cooling and rewarming of the animals
each lasted 1 1/2 h, while the hypothermic period (15 C) lasted
4 h (Fig. 1).
Hemodynamic measurements
Hemodynamic variables were obtained using a pressure–vol-
ume conductance catheter (SPR-838, Millar Instruments Inc.,
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catheter allowed for assessment of in vivo left ventricular (LV)
mechanical function in rats [1]. A constant sinusoidal alternating
current (0.02 mA root means square at 20 kHz) was applied to
drive the conductance catheter, through which changing conduc-
tance was used for the measurement of blood volume. Volume
measurements in this study included parallel conductance (Gp).
Further description of this method and temperature calibration
of the catheter is described in detail in a previous report [8]. The
load-independent LV-contractility index preload recruitable stroke
work (PRSW) was measured by occluding the inferior vena cava
transiently under the diaphragm. According to Filseth et al. this
method was applied only prior to cooling and after rewarming,
as caval occlusions at low temperatures does not induce changes
in PV loops that can be applied to calculate PRSW [5]. To monitor
peripheral vascular responses during cooling and rewarming,
mean arterial pressure (MAP) was measured using a pressure
transducer connected to a fluid-filled catheter (22G) inserted into
the left femoral artery. During experiments, hemodynamic mea-
surements were recorded at the following temperatures: 37, 32,
28, 24, 20 and 15 C.
Experimental design
After surgery, the animals were given 1 ml saline and allowed to
rest for 1 h before start of experiments. Levosimendan or placebo-
levosimendan (placebo) was administered through an i.v. line in
the left femoral vein, extended to the inferior caval vein. Infusion
was started after 3 h of normothermia or hypothermia. The content
of the placebo drug is identical to levosimendan except for absence
of the active substance. Animals in hypothermic groups were core
cooled to 15 C and maintained at this temperature for 4 h, before
rewarming to 37 C. In the normothermic group, animals were held
at 37 C for 5 h.
Normothermic levosimendan group (n = 6)
After 3 h, animals received a bolus dose of 24 lg/kg of levosim-
endan infused over a period of 10 min, followed by a continuous
0.6 lg/kg/min infusion during the last 2 h of experiments.
Hypothermic levosimendan group (n = 7)
After 3 h at stable hypothermia (15 C), animals were infused
with a bolus dose of 24 lg/kg of levosimendan over 10 min, fol-
lowed by a continuous infusion of 0.6 lg/kg/min during the last
hour of hypothermia and till rewarming was completed.
Hypothermic placebo group (n = 7)
After 3 h of stable hypothermia (15 C), animals were infused
with a bolus dose of 24 lg/kg placebo for 10 min, followed by a
continuous infusion of 0.6 lg/kg/min during the last hour of hypo-
thermia and till rewarming was completed.
Measurement of cTnI phosphorylation
After successful rewarming, blood was removed by rapid flush-
ing of sterile saline through the jugular catheter as described ear-
lier [26]. The heart was quickly isolated, the LV dissected out and
flash-frozen in liquid nitrogen. Measurements of the cTnI phos-
phorylation level on PKA associated sites Ser23/24 were performed
using Western blot. The tissue was homogenized with a standard
cell lysis buffer (Cell signaling) with 1 mM PMSF (Sigma). The pro-
tein level was measured with Lowry assay (Bio-Rad DC protein
Assay). 45 lg of protein was loaded in each well separated with
SDS–PAGE and transferred to a polyvinylidene difluoride (PVDF)
membrane (Bio-Rad). Transferred proteins on PVDF membranes
were detected with specific antibodies for either total cTnI(Fitzgerald) or phosphorylated cTnI at Ser23/24 (Cell Signal) and
visualized by a chemo luminescent for detecting horseradish per-
oxidase (Bio-Rad). The bands were quantitatively analyzed using
molecular imaging software (v. 4.0.1 Kodak). The amount of phos-
phorylation is measured as phosphorylation rate (density of phos-
phorylated Ser23/24-cTnI divided by total cTnI).Measurement of cTnI release
After experiments were completed, arterial blood was sampled
from the left femoral artery. Blood was centrifuged and the plasma
extracted from the tubes. Plasma-cTnI was then analyzed, using a
high sensitivity rat cTnI ELISA kit, Life Diagnostics, Inc., West
Chester, PA, USA.Statistics
Changes from baseline in hemodynamic variables were com-
pared by One-way repeated measures ANOVA. When significant
differences were found, Dunnett’s method was used to compare
values within group vs. baseline. Differences in cTnI release
between groups were analyzed using one-way ANOVA on ranks.
When significant differences were found, Dunn’s method was used
to compare values between groups. PRSW data within each group
were compared using a paired t-test. Differences between hypo-
thermic groups at same temperatures and cTnI phosphorylation
between the hypothermic groups after rewarming were measured
using a two-tailed, unpaired Student’s t-test. Differences were con-
sidered significant at p < 0.05.Results
Hemodynamics
Normothermia (Fig. 2)
Hemodynamic effects of levosimendan infusion in normothermic
controls (37 C). Compared to values measured at start of experi-
ment (baseline), levosimendan infusion (120 min) caused signifi-
cant elevation of stroke volume (SV), cardiac output (CO), heart
rate (HR), maximum rate of LV pressure change (LVdp/dtmax) and
stroke work (SW), whereas total peripheral resistance (TPR)
decreased. Hemodynamic stability, up to 5 h at 37 C, has been
documented in numerous other studies using the present intact
rat model [33,12].Stable hypothermia
Levosimendan and placebo groups (15 C). At the end of the 4 h sta-
ble hypothermia period, 1 h after start of placebo or levosimendan
infusions in the two groups, most indexes of hemodynamic func-
tion were significantly reduced from their prehypothermic base-
line values. Exceptions were left ventricular end-diastolic
pressure (LVEDP), left ventricular end-diastolic volume (LVEDV),
left ventricular end-systolic volume (LVESV) and SV, which
remained unchanged. TPR was increased only in the placebo group
(Figs. 3 and 4).
At the end of 4 h stable hypothermia and 1 h of levosimendan or
placebo infusion, TPR was significantly lower and HR significantly
higher in the levosimendan group compared to the placebo group.Rewarming (Figs. 3, 4 and 7)
Placebo group (37 C). After rewarming from 15 C, SV, CO, SW and
PRSW were all significantly reduced when compared to prehypo-
thermic baseline values. TPR remained significantly elevated, when
compared to prehypothermic baseline.
Fig. 2. Hemodynamic parameters in the normothermic control group, receiving levosimendan (bolus dose: 24 lg/kg, continuous infusion: 0.6 lg/kg/min) during the last 2 h
of experiments. EDV: End-diastolic volume, SV: Stroke volume, ESV: End-systolic volume. Values are mean ± SEM. #Significantly different from within group baseline
(p < 0.05). ⁄Significant difference between groups (p < 0.05).
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Fig. 3. Hemodynamic parameters in the two hypothermic groups, receiving either levosimendan or placebo (bolus dose: 24 lg/kg, continuous infusion: 0.6 lg/kg/min)
during the last hour of hypothermia and during rewarming. Values are mean ± SEM. #Significantly different from within group baseline (p < 0.05). ⁄Significant difference
between groups (p < 0.05).
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Fig. 4. Hemodynamic parameters in the two hypothermic groups, receiving either levosimendan or placebo (bolus dose: 24 lg/kg, continuous infusion: 0.6 lg/kg/min)
during the last hour of hypothermia and during rewarming. Values are mean ± SEM. #Significantly different from within group baseline (p < 0.05). ⁄Significant difference
between groups (p < 0.05).
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ing caused a return to within pre-hypothermic baseline values
of most cardiac variables. Minimum rate of LV pressure change
(LVdp/dtmin) was decreased after rewarming, while HR was
increased.Differences between rewarmed levosimendan and placebo groups
(37 C). After rewarming SV, CO, LVdp/dtmax, SW and PRSW were
significantly higher in the levosimendan group compared to the
placebo group. TPR was significantly lower in the levosimendan
group when compared to the placebo group.
Fig. 5. cTnI phosphorylated at the Ser23/24 site in fraction of total cTnI, measured
in left-ventricular tissue from excised hearts after rewarming in the two hypother-
mic groups, receiving either levosimendan or placebo (bolus dose: 24 lg/kg,
continuous infusion: 0.6 lg/kg/min) during the last hour of hypothermia and
during rewarming: Values are mean ± SEM. ⁄Significant difference between groups
(p < 0.05).
Fig. 6. Plasma-cTnI levels in the normothermic control group, receiving levosim-
endan (bolus dose: 24 lg/kg, continuous infusion: 0.6 lg/kg/min) during the last
2 h of experiments and in the two hypothermic groups, receiving either levosim-
endan or placebo (bolus dose: 24 lg/kg, continuous infusion: 0.6 lg/kg/min) during
the last hour of hypothermia and during rewarming: Values are mean ± SEM.
⁄Significant difference between groups (p < 0.05).
Fig. 7. Preload recruitable stroke work before cooling and after rewarming in the
two hypothermic groups, receiving either levosimendan or placebo (bolus dose:
24 lg/kg, continuous infusion: 0.6 lg/kg/min) during the last hour of hypothermia
and during rewarming: Values are mean ± SEM. #Significantly different from within
group baseline (p < 0.05). ⁄Significant difference between groups (p < 0.05).
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After rewarming, Ser23/24-cTnI phosphorylation was signifi-
cantly increased in the levosimendan group when compared to
the placebo group. Phosphorylation results are displayed as a ratio
between Ser23/24-cTnI phosphorylation and total cTnI protein.
cTnI release (Fig. 6)
Level of plasma-cTnI release at the end of experiments showed
significant differences when comparing the normothermic group
with both the rewarmed levosimendan group, and rewarmed pla-
cebo group. No significant differences were found between the
rewarmed groups.
Discussion
Levosimendan administered during the last hour of hypother-
mia (4 h, 15 C) and throughout rewarming to 37 C caused areturn to within prehypothermic levels of SV, CO and PRSW. This
is essentially different from the significant reduction of these vari-
ables after rewarming in the placebo group, demonstrating the
positive inotropic effect of levosimendan during both hypothermia
and rewarming.
Several inotropic drugs have been tested in the pursuit to phar-
macologically elevate SV during rewarming from hypothermia. The
present study demonstrates that levosimendan ameliorates hypo-
thermia-induced cardiac dysfunction by elevating SV to pre-
hypothermic levels after rewarming. This stand in stark contrast
to our previous studies on b-receptor agonists, demonstrating that
the inotropic properties of such drugs are altered during hypother-
mia and rewarming [14,12,8,28]. In more detail, only low-dose
(0.125 lg/min) epinephrine showed beneficial hemodynamic
effects when administered throughout rewarming from 15 C. Ele-
vation of SV was not achieved by higher epinephrine doses like in
normothermia and vasoconstriction was induced [12], This shows
that low core temperatures narrow the therapeutic window of ino-
tropic treatment with b-agonists. The apparent challenges in pro-
viding cardiovascular pharmacological support during rewarming
of hypothermic patients is reflected by recommendations in both
the European [23] and American [31] guidelines, where adminis-
tration of drugs is recommended only at core temperatures above
30 C. Our findings indicate that use of inotropic support during
hypothermia as well as rewarming from low core temperatures
can provide favorable hemodynamic effects and ameliorate hypo-
thermia-induced cardiac dysfunction. In the present study, we
have demonstrated these favorable effects during rewarming after
4 h exposure to 15 C, when applying a levosimendan-dose equiv-
alent to what is defined as a high dose in clinical medicine. Others
have also reported positive effects of lower doses of levosimendan
during 15 min exposure to core-temperatures at 13–15 C in pre-
clinical studies of thoracic surgery [21,22]. These findings indicate
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wider therapeutic window than for b-receptor agonists during
hypothermia and rewarming.
The present experiment shows that levosimendan facilitates
Ser23/24-cTnI phosphorylation when administered during
rewarming from 15 C. Phosphorylation of cTnI is well documented
and three main phosphorylation sites are explored: Ser23/24,
Ser43/45 and Thr144, which are targeted by various kinases. PKA,
a downstream kinase from cAMP in the pathway stimulated by
b-receptor agonists and PDE3 inhibition, has shown great specific-
ity for Ser23/24 [24]. Phosphorylation of this site is associated with
reduced myofilament calcium-sensitivity [19]. Interestingly, Han
et al. found that site-specific cTnI phosphorylation at Ser23/24
was increased after rewarming from 15 C in rat papillary muscle
and related this to contractile dysfunction [9]. The ability of levo-
simendan to support cardiac function and avoid stimulation of
the cAMP–PKA pathway, thereby preventing further Ser23/24-cTnI
phosphorylation, has earlier been used to describe the positive ino-
tropic effect of this drug during rewarming after a short exposure
to hypothermia [22]. However, positive inotropic effect of stimu-
lating the cAMP, – PKA pathway through PDE3-inhibition during
hypothermia, have already been observed in our rat model, using
milrinone [27]. Levosimendan is also known to inhibit PDE3 in
high doses as used in the present study [25,3], and we found
increased Ser23/24-cTnI phosphorylation when compared to the
placebo group after rewarming. This indicates that levosimendan
facilitated cAMP, – PKA mediated Ser23/24-phosphorylation of
cTnI via PDE3 inhibition and was observed in the presence of
restored contractile function (PRSW) in the levosimendan group
after rewarming. We therefore suggest that the combined PDE3
inhibition and calcium sensitizing mediated by levosimendan
overcomes the potential negative inotropic effects of increased
Ser23/24-cTnI phosphorylation [9]. Furthermore, at low core tem-
peratures the importance of PDE3 inhibition might be enhanced
due to hypothermia-induced cTnI phosphorylation [9], which is
reported to decrease the calcium-sensitizing effect of levosimen-
dan [10]. Despite offering positive inotropic effect, levosimendan-
treatment did not protect against release of the myocardial injury
marker plasma-cTnI. Increased release of this injury marker after
rewarming also in the hypothermic placebo group, but not in the
normothermic controls, shows that hypothermia caused myocar-
dial tissue injury.
The positive inotropic effect of PDE3 inhibition reported in the
present and previous studies [27], strongly indicates that stimula-
tion of the cAMP, – PKA pathway through inhibition of cAMP deg-
radation is favorable during rewarming. Efforts to stimulate this
pathway through b-receptor agonists however, have demon-
strated impaired inotropic properties of such drugs already during
cooling to moderate hypothermia (34–33 C) [8,28]. One mecha-
nism facilitating this could be hypothermia-induced changes in
b-receptor function. Interestingly, both increased and decreased
b-receptor sensitivity is reported at low temperatures [15,32]
and underlying mechanisms for diminished effect of b-agonists
during hypothermia still remains unclear. Thus, more knowledge
about the effects of hypothermia on b-receptor function is
needed.Conclusion
The present experiment shows positive inotropic effect of levo-
simendan during rewarming, when combining the calcium sensi-
tizing and the PDE3 inhibitory effects offered by a high-dose of
this drug. We therefore suggest that at low core temperatures,
pharmacologic efforts to elevate cardiac function are better
achieved by stabilization of the cTnC–cTnI complex and preventionof cAMP breakdown, rather than by attempting to increase cAMP
formation via b-receptor stimulation.Acknowledgments
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Background: Rewarming from hypothermia is associated with depressed cardiac function, known as
hypothermia-induced cardiac dysfunction (HCD), and increased systemic vascular resistance (SVR).
Previous studies on pharmacological treatment of HCD have demonstrated beneficial effects when using
drugs with the combined effects; cardiac inotropic support and peripheral vasodilation. The presented
study aims to investigate the isolated effects of arterial dilatation on cardiac functional variables during
rewarming from hypothermia using sodium nitroprusside (SNP).
Methods: We utilized a rat model designed to induce HCD following 4 h at 15 C and rewarming. To study
effects on left ventricular (LV) functional variables in response to afterload reduction by SNP during
rewarming a conductance catheter was used. Index of LV contractility, preload recruitable stroke work
(PRSW), was obtained with inferior vena cava occlusions at 37 C before and after hypothermia. Pressure
signals from a catheter in the left femoral artery was used to pharmacologically adjust SVR.
Results: After rewarming both animal groups showed significant reduction in both SV and CO as a
manifestation of HCD. However, compared to saline controls, SV and CO in SNP-treated animals increased
significantly during rewarming in response to afterload reduction displayed as reduced SVR, mean
arterial- and end-systolic pressures. The cardiac contractility variable PRSW was equally reduced after
rewarming in both groups.
Conclusion: When rewarming the present model of HCD a significant increase in SVR takes place. In this
context, pharmacologic intervention aimed at reducing SVR show clear positive results on CO and SV.
However, a reduction in SVR alone is not sufficient to fully alleviate CO during HCD, and indicate the need
of additional inotropic support.
© 2017 Published by Elsevier Inc.1. Background
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etrichs), torkjel.tveita@uit.notreatment of accidental hypothermia victims [5,28,38]. In experi-
mental models of hypothermia and rewarming, HCD has been
identified as a key mechanism underlying rewarming shock
[35,39]. Being a feared complication, rewarming shock develops as
the cardiovascular system fails to provide adequate perfusion
during rewarming and contributes to the high lethality in acci-
dental hypothermia victims [5,28], reported to be between 28 and
35% [22,31,42]. Clinically, patients present with symptoms of low
cardiac output (CO) accompanied by a rapid drop in blood pressure,
despite restoration of core temperature [5].
Previous experiments have reported positive effects of milri-
none and levosimendan on stroke volume (SV) and CO and when
applied during rewarming in attempts to alleviate HCD [6,7]. The
documented increase in cardiac function of these drugs is mainly
attributed their direct positive inotropic effects. However, the
B. Håheim et al. / Cryobiology 77 (2017) 75e8176beneficial effects were accompanied by a reduction inmean arterial
pressure (MAP) and systemic vascular resistance (SVR) explained
by the well documented vasodilating effects of these drugs [26]. In
normal physiology, vasodilatation reduces SVR and alleviate cardiac
work and afterload, elevating CO [11]. This has also been demon-
strated in patients with ischemic heart failure and cardiogenic
shock where SVR reduction improved left-ventricular function and
CO [3]. The beneficial effects of levosimendan and milrinone on
HCD stand in contrast to the effects of adrenaline documented in
the same experimental model. Unlike levosimendan or milrinone,
adrenaline increased SVR and failed to alleviate CO during hypo-
thermia and rewarming [8,12,19].
Cardiovascular physiology research has demonstrated that the
relationship between CO and MAP is determined by four principal
factors; SVR, cardiac pumping capacity (CPC), blood volume, and
vascular compliance [11]. The beneficial effects of levosimendan
and milrinone to elevate CO take place by simultaneously
increasing CPC by Ca2þ-sensitization and phosphodiesterase-3 in-
hibition and by reducing SVR via peripheral vasodilation through
opening of smooth muscle KþATP-channels and phosphodiesterase-
3 inhibition [26]. As both SV and SVR are altered in HCD, the
combined pharmacological effects of levosimendan and milrinone,
to support cardiac inotropy and induce vasodilatation, complicate
the interpretation of the hemodynamic data. In a quest to amelio-
rate and understand HCD and rewarming shock, it is important to
determine the separated effects of vasodilatation and positive
inotropy.
Different from milrinone and levosimendan, sodium nitro-
prusside (SNP) is a potent vascular vasodilator with no inotropic
effects [33]. It has beenmeticulously studied and are readily used in
both clinical practice and in basic research and has demonstrated to
improve cardiac function during cardiogenic shock and when used
after rewarming from hypothermia in dog [3,24,32,34]. SNP relax
smooth muscle and reduce SVR by nitric oxide activation of the
cGMP-pathway. In vitro studies report possible inotropic support of
SNP on cardiomyocytes [18,23]. However, in vivo experiments finds
no clinical relevant changes in contractile parameters in healthy
and failing hearts [33].
The aim of this study is to investigate if reduction in SVR during
rewarming from experimental hypothermia may improve cardiac
function. To test this we applied SNP in comparison with non-
treated saline controls in a well-established in vivo rat model of
HCD equipped for invasive hemodynamic monitoring [6,7,19].
2. Materials and methods
2.1. Animals
MaleWistar rats (n¼ 14, meanweight 313.8 g ± 7.18) were used.
Animals were obtained from Charles River and quarantined for 1
week before experiment. Housing was provided in accordance with
guidelines for accommodation and care of animals (article 5 of the
European Convention for the Protection of Vertebrate Animals used
for Experimental and Other Scientific Purposes, Strasbourg,
18.III.1986). The rats had a microbiological status per the recom-
mendation of the Federation of European Laboratory Animal Sci-
ence Associations. The animals had ad libitum access to water and
food. The experimental protocol was approved by the Norwegian
Animal Research Authority and conducted accordingly.
2.2. Anesthesia
Before vivisection, the animals were anesthetized with 50 mg/
kg sodium pentobarbital and 0.05 mg/kg fentanyl with an intra-
peritoneal bolus injection. The animals received 7.5 mg/kg/hsodium pentobarbital and 0.05 mg/kg/h fentanyl through a pedi-
atric central venous catheter placed in the right jugular vein. Cold
narcosis occurs <30 C, pharmacological anesthesia was therefore
discontinued <30 C and continued upon rewarming [27]. Pain and
discomfort was monitored with the toe-pinch method as well as
hemodynamic markers of stress. Toe-pinch is a well-known and
established method to determine the depth of anesthesia in ro-
dents [4,7,19].
2.3. Respiratory support
Airways were secured by a tracheostomy followed by insertion
of a tracheal tube. In this model apnea occurred at around 20 C,
whereby mechanical ventilation with a small rodent ventilator is
started (Kent Scientific, USA). Mechanical ventilation was dis-
continued once spontaneous respiration returned upon rewarming.
2.4. Hemodynamic measurements
Continuous cardiac volume and pressure measurements were
provided through cannulation of the left carotid artery with a 2.0
French conductance catheter (SPR-838, Millar Instruments Inc.,
USA) placed in the left ventricle [2]. The conductance catheter
technique and calibration is previously described in detail in earlier
reports [6,7,12]. A fluid filled 22G catheter placed in the left femoral
artery provided systemic arterial pressure measurement. Both
catheters were connected to a PowerLab 16/30 transducer (ADIn-
struments, New Zealand), and the data was recorded and analyzed
using LabChart 7 (ADInstruments, New Zealand). Hemodynamic
data was recorded at 37 C, 32 C, 28 C, 24 C, 20 C, and hourly for
4 h at 15 C. To assess cardiac contractility, preload recruitable
stroke work (PRSW) was obtained by occluding the inferior vena
cava at 37 C baseline and after rewarming. The reduced hemo-
dynamic function during hypothermia <20 C prohibited vena cava
occlusions and therefore PRSW values was not obtainable during
the hypothermia protocol [6,10].
2.5. Cooling and rewarming
Temperature control was obtained with a water bath (Ther-
mostat water bath type RTE-110, Neslab Instruments, USA) circu-
lating cold or warm water through a U-shaped polyethylene tube
gently inserted into the intestine. In addition, the water bath was
connected to a hollow, double walled, aluminum surgical table
providing external heating and cooling. Temperature was contin-
uously monitored with the use of an esophageal thermocouple (T-
type) connected to a transducer (Colombia Instruments, USA). Both
cooling and rewarming of the animals lasted 90 min, while the
hypothermic period lasted 4 h (Fig. 1).
2.6. Sodium nitroprusside and saline
Sodium nitroprusside (Nitropress®) from Hospira (IL, USA)
(25 mg/mL) was used. On the day of experiment, the sodium
nitroprusside stock was diluted to 0.125 mg/ml (1:200) in 5%
glucose [17]. As placebo in the saline control group 0.9% NaCl
(Fresenius Kabi, Germany) was used.
2.7. Experimental design and pharmacological intervention
Two experimental groupswere included in this study. Group 1e
Saline and Group 2 e Nitroprusside. After surgery, all animals
received 1 mL saline with 10 IE Heparin/mL and were allowed to
stabilize for 1 h before cooling. Both groups were subjected to 4 h of
hypothermia at 15 Cwith subsequent rewarming. Pharmacological
Fig. 1. Temperature profile of all 14 hypothermic rats, showing cooling (37-15C), 4 h
stable hypothermia (15C) and rewarming (15e37C). Values are mean.
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throughout rewarming. Saline (Group 1) was infused with a bolus
dose of 0.83 ml 0.9% saline over 20 min, followed by a continuous
infusion of 0.5 mL/h. Nitroprusside (Group 2) infusion started at
0.625 mg/kg/min and was titrated to reduce MAP by 30% during
rewarming.
2.8. Statistical analysis
The hemodynamic progression in each group was analyzed with
a repeated measurement one-way ANOVA. Data distribution was
tested with Shapiro-Wilks test, and if failed (p < 0.05) an ANOVA on
ranks test was utilized. If the null-hypothesis (H0) was rejected
(p < 0.05), a post-hoc Dunnett's test was performed to analyze
differences from pre-hypothermic baseline values. Between-groups
comparisons at each time-point were done with a two-tailed Stu-
dents t-test. Data distribution was tested with Shapiro-Wilks test,
and if failed (p< 0.05) aMann-Whitney U test was utilized. A paired
t-test was used to compare PRSW at 37 C before cooling vs. after
rewarming. Statistical significance was accepted at p < 0.05. All
results are presented as mean ± SEM.
3. Results
3.1. Dose-finding study
We used MAP as a surrogate for SVR during drug administration
in the dose-finding study. To mimic the vascular vasodilator effects
of milrinone during hypothermia and rewarming we determined a
30% reduction in MAP as target [6,7]. When using the same dose
SNP (10 mg/kg/min) as normothermia during 15 C, severe hypo-
tension and cardiac standstill occurred [16]. Therefore, from a dose-
finding study we found that at 15 C a 20-fold dose-reduction of
SNP was required to achieve the target reduction of MAP which at
the same time gave an acceptable hemodynamic function.
Accordingly, SNP infusion started with 0.6125 mg/kg/min at 15C3.
Once rewarming was started the vasodilatory effects of nitroprus-
side diminished and infusion rate was dynamically increased to
achieve target MAP.
3.1.1. Within-group comparisons (Table 1)
3.1.1.1. Group 1 e saline. Compared to baseline (37CBL) a signifi-
cant reduction was found in heart rate (HR), mean arterial pressure(MAP), LV end-systolic pressure (ESP), cardiac output (CO), and LV
peak rate of pressure rise (dP/dTmax) after cooling to 15 C (15C0).
Moreover, LV peak rate of pressure decline (dP/dTmin) and Tau were
increased. After rewarming (37CRW) a significant reduction in
MAP, SV, CO, dP/dTmax, SW and preload recruitable stroke work
(PRSW) was found when compared to 37CBL. Also, a significant
increase in dP/dTmin and SVR was found (Table 1, Fig. 3).
3.1.1.2. Group 2 e sodium nitroprusside (SNP). After cooling to
15C0 a significant reduction in HR, MAP, ESP, CO, dP/dTmax and SW
was found compared to 37CBL. Tau, dP/dTmin, and SVR was
significantly incased. After rewarming to 37CRW there was a sig-
nificant reduction in MAP, ESP, SV, CO dP/dTmax, SW and PRSW,
whereas a significant increase in dP/dTmin was found when
compared to 37CBL (Table 1, Fig. 3).
3.1.2. Between-group comparisons (Figs. 2 and 3)
3.1.2.1. Baseline, cooling and hypothermia (37CBL - 15C3). No sig-
nificant difference was found in any hemodynamic parameters
between groups at 37CBL, after cooling to 15C0 or after 3 h of
hypothermia (15C3) prior to pharmacological intervention.
3.2. Pharmacological intervention and rewarming (15C3 - 32CRW)
Throughout rewarming from 15C4 a significant reduction in
MAP and ESP was present at all time-points in SNP treated animals
compared to saline. Further, SVwas significantly elevated at 32CRW
and SW significantly depressed at 20CRW, 24CRW and 28CRW in
the SNP treated animals. No difference was found between groups
in HR, dP/dTmax, CO, SVR or Tau throughout rewarming to 32CRW.
3.3. After rewarming (37CRW)
After rewarming to 37 C, MAP, ESP and SVR were significantly
lowered, and SV and CO significantly elevated in animals treated
with SNP compared to saline. No difference was found in HR, dP/
dTmax, PRSW and SW.
4. Discussion
This study demonstrates that dynamic reduction of SVR,
enabled by peripheral arteriolar vasodilatation with sodium
nitroprusside (SNP), alleviated cardiac workload and elevated post-
hypothermic SV and CO when compared to non-treated controls.
However, the vasodilator effects achieved by SNP were not able to
restore cardiac function to pre-hypothermic levels.
4.1. Nitroprusside in hypothermia
This study is the first to show maintained vasodilator effects of
SNP also at temperatures down to 15 C. Further, we found that by
reducing MAP, to achieve the wanted reduction in SVR, a simulta-
neous increase in CO and SV took place. This was not a result of
altered cardiac contractility as dP/dTmax, SW and PRSW was iden-
tical between the groups at 37CRW. This is in concordance with
studies on the inotropic effects of SNP as they show unaltered
contractility in both healthy and failing hearts [33]. Interestingly,
SNP infusion rate had to be rapidly increased throughout
rewarming to achieve targetMAP. Boon et al. showed that the dose-
response of SNP is strongly dependent on intra-vascular fluid vol-
ume and CO [1]. Pharmacodynamical effects of SNP is increased in
the presence of elevated preload and CO, while it is reduced in a
setting with low preload and reduced CO [1]. Treatment of hypo-
thermia entails significant changes in circulating blood volume and
a dynamic increase in CO during the rewarming phase [20,40].
Table 1
Hemodynamic parameters, and systolic and diastolic indicators at four staple time points: 37CBL, 15C0, 15C4 and 37CRW. Values are mean ± SEM.* indicate significate
difference from 37CBL within groups (p < 0.05).
Parameter Group 37CBL 15C0 15C4 37CRW
Heart rate, beats/min Saline 435 ± 15 50 ± 2* 48 ± 2* 458 ± 16
Nitroprusside 443 ± 14 48 ± 2* 51 ± 3* 462 ± 12
MAP, mmHg Saline 120.7 ± 7.6 36.5 ± 2.9* 31.2 ± 2.0* 106.1 ± 2.0*
Nitroprusside 112.5 ± 2.8 42.8 ± 4.7* 21.2 ± 1.0* 79.3 ± 6.5*
ESP, mmHg Saline 135.1 ± 6.7 73.4 ± 6.4* 56.3 ± 4.4* 125.9 ± 6.0
Nitroprusside 129.1 ± 2.9 72.1 ± 5.9* 37.2 ± 2.0C* 87.6 ± 5.4*
SV, mL Saline 63.6 ± 10.5 141.6 ± 14.6* 82.8 ± 9.4 21.5 ± 3.3*
Nitroprusside 64.6 ± 7.4 113.7 ± 14.4* 68.7 ± 6.4* 36.1 ± 4.8*
CO, mL/min Saline 27.78 ± 4.76 7.71 ± 0.73* 3.91 ± 0.39* 9.74 ± 1.35*
Nitroprusside 28.56 ± 3.28 6.35 ± 0.99* 3.63 ± 0.47* 16.45 ± 1.83*
SVR, mmHg/mL/min Saline 5.19 ± 0.96 5.03 ± 0.63 8.3 ± 0.68 12.8 ± 2.51*
Nitroprusside 4.22 ± 0.45 8.27 ± 1.77* 6.87 ± 1.46 5.36 ± 0.86
Systolic indicators
dP/dTmax, mmHg/s Saline 10630 ± 864 1668 ± 132* 1139 ± 146* 8158 ± 68*
Nitroprusside 10753 ± 454 1973 ± 215* 784 ± 103* 7781 ± 791*
SW, mmHg*mL Saline 7.65 ± 1.20 7.25 ± 0.71 3.36 ± 0.45 1.82 ± 0.23*
Nitroprusside 7.54 ± 0.97 6.00 ± 0.78 1.72 ± 0.17* 2.42 ± 0.22*
PRSW, mmHg Saline 109.10 ± 7.38 e e 63.40 ± 15.21*
Nitroprusside 102.99 ± 9.45 e e 62.14 ± 8.94*
Diastolic indicators
dP/dTmin, mmHg/s Saline 11031 ± 720 560 ± 49* 480 ± 48* 9079 ± 514*
Nitroprusside 12961 ± 565 596 ± 95* 327 ± 39* 7778 ± 681*
Tau, ms Saline 7.70 ± 0.47 72.62 ± 4.37* 77.25 ± 5.97* 8.42 ± 0.74
Nitroprusside 9.13 ± 0.17 96.60 ± 12.81* 41.81 ± 3.49* 6.66 ± .35
B. Håheim et al. / Cryobiology 77 (2017) 75e8178These changes would explain the need for rapid dose adjustments
during rewarming to maintain a reduced MAP. The dynamic and
easily reversed effects of SNP during rewarming provide an op-
portunity to titrate infusion rate to prevent hemodynamic insta-
bility. As SNP breakdown occurs via a reaction inside erythrocytes
involving hemoglobin the half-life is independent of liver and
kidney metabolism [17]. This prevents an increase in half-life of
SNP at low temperatures, as seen with many other vasoactive
substances during hypothermia [41]. This enables an easy revers-
ibility of SNP and offers a clinical advantage over drugs with
temperature-dependent prolongation of half-life when applied
during rewarming from hypothermia.4.2. Hypothermia, vascular resistance and rewarming shock
Elevated SVR during hypothermia has previously been claimed
to result from temperature-induced increase in blood viscosity
[25]. As demonstrated in the present study, SVR continued to in-
crease in the saline group, despite normalized blood viscosity upon
rewarming, as demonstrated by Poulos [29]. This indicates
involvement of other mechanisms underlying the elevated post-
hypothermic SVR. Changes in SVR depend on vascular smooth
muscle tone and endothelial function [15]. So far, no descriptive
literature is available on smooth muscle function during hypo-
thermia and rewarming. Investigators have, however, documented
that hypothermia and rewarming may cause endothelial damage
and dysfunction [14,30,43]. The lowered SVR by SNP, milrinone and
levosimendan demonstrate that endothelium-independent vaso-
dilatation is achieved also during hypothermia. In more detail, this
indicates that vascular smooth muscle responds to nitric oxide and
elevated cyclic AMP in a similar way both in hypothermic and
normothermic conditions, as already suggested [32,36]. These
findings may indicate that hypothermic and post-hypothermic
elevation of SVR is not a compensatory mechanism or solely the
result of increased blood viscosity, but possibly a consequence of
hypothermia-induced vascular dysfunction because of endothelial
damage. Endothelial damage may well be a result of exposure to
long-lasting and profound hypothermia as in the presentexperiment.
The presented study finds that pharmacologic elevation of CO
can be achieved during HCD in the absence of specific cardiac
inotropic support. These findings provide nuance and increase
emphasis on the heart-vasculature relationship during hypother-
mia and rewarming. Further, the present data provide new insight
to why inodilatators such as milrinone, levosimendan and dopa-
mine may elevate CO to pre-hypothermic values after rewarming
[6,7,9], whereas the inoconstrictor adrenaline caused a significant
reduction of CO and SV by elevating SVR [8,19]. While SNP showed
beneficial effect on CO after rewarming, the absence of additional
inotropic support explains why SNP as monotherapy failed to re-
turn CO to pre-hypothermic levels. This shows that the key to
proper pharmacological treatment of HCD and rewarming shock is
the combination of cardiac inotropic support and appropriate SVR
regulation. Finally, as this is an animal study it is important not to
translate the presented findings to clinical recommendations
without careful consideration and awareness of animal model
limitations. However, the model used has demonstrated to be
reproducible in multiple species and believed to accurately repre-
sent the human condition of rewarming shock [10,13,21,37].
Further, SNP is a well-tested and used drug in clinical practice and
research, with demonstrated beneficial effects in human cardiac
disease [3,32,34]. This strengthens our conviction that the pre-
sented findings are relevant to the clinical situation and that this is
a track worth pursuing in further animal studies.5. Conclusion
This experiment shows that CO is elevated if SVR is dynamically
reduced by SNP-induced vasodilatation during rewarming from
hypothermia. The elevated SVR found in untreated animals during
rewarming seems to have negative hemodynamic effects, rather
than functioning as a compensatory mechanism, especially when
heart function suffers from HCD. However, the SNP-induced
reduction of SVR alone is not sufficient to fully alleviate CO dur-
ing HCD, and indicate the need for supplemental inotropic support
during rewarming of hypothermic patients.
Fig. 2. Hemodynamic variables during cooling, hypothermia and rewarming in both experimental groups. Values are mean ± SEM. # indicate Group 2 - Nitroprusside is significantly
different from Group 1 - Saline (p < 0.05).
Fig. 3. Hemodynamic variables during cooling, hypothermia and rewarming in both experimental groups. Values are mean ± SEM. # indicate Group 2 - Nitroprusside is significantly
different from Group 1 - Saline (p < 0.05). þ indicate 37CRW significantly different from 37CBL (p < 0.05).
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